USH2007H1 - Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines - Google Patents

Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines Download PDF

Info

Publication number
USH2007H1
USH2007H1 US08/780,371 US78037197A USH2007H US H2007 H1 USH2007 H1 US H2007H1 US 78037197 A US78037197 A US 78037197A US H2007 H USH2007 H US H2007H
Authority
US
United States
Prior art keywords
phenyl
halogen
composition
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US08/780,371
Inventor
Ian R. Silverman
Syed F. Ali
Daniel H. Cohen
John W. Lyga
Kirk A. Simmons
Thomas G. Cullen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FMC Corp
Original Assignee
FMC Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FMC Corp filed Critical FMC Corp
Priority to US08/780,371 priority Critical patent/USH2007H1/en
Priority to AU15809/97A priority patent/AU1580997A/en
Priority to PCT/US1997/000804 priority patent/WO1997026252A1/en
Assigned to FMC CORPORATION reassignment FMC CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SILVERMAN, IAN R., ALI, SYED F., COHEN, DANIEL H., CULLEN, THOMAS G., LYGA, JOHN W., SIMMONS, KIRK A.
Application granted granted Critical
Publication of USH2007H1 publication Critical patent/USH2007H1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • C07D213/6432-Phenoxypyridines; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • C07D213/85Nitriles in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/101,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/192Radicals derived from carboxylic acids from aromatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Definitions

  • the present invention relates to methods for controlling insects.
  • it relates to control by application of certain N-heterocyclylalkyl- or N-[(polycyclyl)alkyl]N′-substituted piperazine derivatives to locus where insect control is needed.
  • certain N-heterocyclylalkyl- or N-[(polycyclyl)alkyl]N′-substituted piperazine derivatives to locus where insect control is needed.
  • the use of the compounds of the invention as insecticides is heretofore unknown.
  • a and B are independently selected from lower alkyl
  • U is selected from lower alkyl, lower alkenyl, CH—Z, where Z is independently selected from hydrogen, lower alkyl, lower cycloalkyl, and phenyl;
  • R is selected from phenyl, optionally substituted with halogen, lower alkyl, lower alkoxy, phenyl, or phenoxy, and from polycyclyl, optionally substituted with halogen, lower alkyl, or lower alkoxy, where polycyclyl is a dibenzocyclo(C 5-8 )alkyl;
  • R 3 and R 4 are independently selected from phenyl, optionally substituted with halogen, lower alky, lower haloalkyl, lower alkoxy, lower haloalkoxy, lower alkenyl, or phenyl;
  • R 1 is phenyl, naphthyl, tetrazolylphenyl, phenylcyclopropyl, phenoxyphenyl, benzyloxyphenyl, pyridylphenyl, pyridyloxyphenyl, thiadiazolyloxyphenyl, benzothienyl, benzimidazolyl, indolyl, pyrrolyl, or quinolyl, each optionally substituted with halogen, cyano, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy, amino, lower dialkylamino, nitro, lower haloalkylsulfonyloxy, lower alkylcarbonyloxy, lower alkylcarbonylamino, lower alkoxycarbonyl, lower alkoxyalkoxycarbonyl, lower cycloalkylalkoxycarbonyl, lower alkoxyalkylalkoxycarbonyl, lower alkoxycarbonylamino,
  • D, E, and G are independently selected from hydrogen, halogen, cyano, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy, nitro, lower haloalkylsulfonyloxy, lower alkylcarbonyloxy, lower alkylcarbonylamino, arylcarbonylamino, lower alkylcarbonyl, lower alkoxycarbonyl, or D and E taken together may form the group —O(CH 2 )O—, and J is hydrogen or lower alkyl;
  • n 1 or 3;
  • halogen is chlorine, fluorine, or bromine, lower means having from 1 to 6 carbon atoms and any aliphatic chain of three or more carbons may be straight or branched.
  • Preferred compounds are those in which
  • U is CH 2 ;
  • R 3 and R 4 are independently selected from chlorophenyl, fluorophenyl, methylphenyl, trifluoromethylphenyl, methoxyphenyl, and trifluoromethoxyphenyl;
  • R 1 is phenyl, tetrazolylphenyl, pyridylphenyl, pyridyloxyphenyl; each optionally substituted with halogen, cyano, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy, amino, lower dialkylamino, lower alkylcarbonyloxy, lower alkylcarbonylamino, lower alkoxycarbonyl, lower alkoxyalkoxycarbonyl, lower cycloalkylalkoxycarbonyl, lower alkoxyalkylalkoxycarbonyl, or lower alkoxycarbonylamino; or lower alkyl substituted with any one of the foregoing cyclic R 1 groups; or 3-R 2 , where R 2 is
  • D is hydrogen, hydroxy, chloro, fluoro, methyl, methoxy, or phenylcarbonylamino
  • E and G are independently selected from hydrogen, chloro, fluoro, methyl, and methoxy, with the proviso that when R 1 is lower dialkylaminophenyl, R 3 and R 4 are each trifluoromethoxyphenyl;
  • halogen is chlorine or fluorine, for aliphatic groups lower means having from 1 to 3 carbon atoms and for alicyclic groups lower means having 3 to 6 carbons.
  • U is CH 2 ;
  • R 3 and R 4 are independently selected from 4-chlorophenyl, 4-fluorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, and 4-trifluoromethoxyphenyl;
  • R 1 is phenyl substituted in the 4-position with lower dialkylamino, lower alkoxycarbonylamino, tetrazolyl, pyridyl, or pyridyloxy; each tetrazolyl or pyridyl group optionally substituted with halogen, cyano, lower alkyl, lower haloalkyl, or lower alkoxy; or 3-R 2 , where R 2 is
  • D is hydrogen, 4-chloro, 4-fluoro, 4-hydroxy, or 4-phenylcarbonylamino
  • E is hydrogen, 5-chloro, 5-methyl, or 6-fluoro
  • G is hydrogen or 5-methoxy
  • halogen is chlorine or fluorine, for aliphatic groups lower means having from 1 to 3 carbon atoms and for alicyclic groups lower means having 3 to 6 carbons.
  • N-heterocyclylalkyl- or N-[(polycyclyl)alkyl]-N′-substituted piperazine derivatives of the present invention were prepared by methods known to one skilled in the art. A number of synthesis routes were employed in obtaining the targeted compounds.
  • diaryl methanol (C) is then treated with thionyl chloride affording a (substituted diaryl)methyl chloride (E), for example, (2-chlorophenyl)(4-chlorophenyl)methyl chloride.
  • E substituted diarylmethyl chloride
  • the so-prepared diaryl methyl chloride (E) can then be reacted with piperazine to form the N-[(substituted diaryl)methyl]piperazine (F).
  • the piperazine (F) can be reacted with an appropriate halide (G), affording the targeted N-(substituted alkyl)-N′-[(substituted diaryl)methyl]piperazine (H), for example, N-(4-chloroindol-3-yl-methyl)-N′-[(4-chlorophenyl)(2-chlorophenyl)methyl)piperazine.
  • a substituted indole (I) capable of undergoing a Mannich-type reaction is condensed with formaldehyde and the N-substituted piperazine in dioxane and acetic acid to afford the targeted N-(substituted alkyl)-N′-(R-substituted)-piperazine (J), for example, N-(benzo[ ⁇ ]ythien-3-ylmethyl)-N′-[bis(4-chlorophenyl)methyl]piperazine.
  • Example 1 provides the detailed procedure for this route.
  • those compounds in which Z is other than hydrogen are prepared by first reacting a substituted indole (I) with phosphorus oxychloride and N,N-dimethylformamide, affording the corresponding substituted aldehyde (K).
  • K is in turn condensed with N-[(substituted diaryl)-methyl]piperazine (F) to form the imine and then reacted with the appropriate alkyl or aryl magnesium halide, for example, phenyl magnesium chloride, affording the targeted N-[(alkyl)(substituted indole)alkyl]- or N-[(aryl)(substituted heterocyclyl)alkyl]-N′-[(substituted diaryl)methyl]piperazine (L), for example, N-[(phenyl)(4-chloroindol-3-yl)methyl]-N′-[bis(4-chlorophenyl)-methyl]piperazine.
  • the appropriate alkyl or aryl magnesium halide for example, phenyl magnesium chloride
  • the substituted indole (I) can also be reacted with an aldehyde and N-[(substituted diaryl)methyl]piperazine (F) under acidic conditions, affording the targeted N-[(alkyl)(substituted heterocyclyl)alkyl]- or N-[(aryl)(substituted heterocyclyl)alkyl]-N′-[(substituted diaryl)methyl]piperazine (L).
  • Examples 2 and 4 provide detailed procedures for this route.
  • N-[(substituted diaryl)methyl]piperazine (F) can be reacted with an appropriately substituted aldehyde for example, 4-dimethylaminobenzaldehyde, under acidic conditions and at 100 ° C., affords the targeted N-(substituted alkyl)-N′-[(substituted diaryl)methyl]piperazine (M).
  • an appropriately substituted aldehyde for example, 4-dimethylaminobenzaldehyde
  • Schema 3 outlines routes to compounds where the tether U is varied.
  • An acid chloride (N) is derivatized with an appropriate N-[(substituted diaryl)-methyl]piperazine (E), affording the targeted N-[(substituted)alkylcarbonyl]-N′-[(substituted diaryl)methyl]piperazine (O).
  • the piperazine (O) can also be prepared by derivatizing a substituted carboxylic acid (P), for example, 2-methyl-3-indoleacetic acid, with an appropriate N-[(substituted diaryl)methyl]-piperazine (F).
  • the piperazine (O) is then converted to the targeted N-(substituted alkyl)-N′-[(substituted diaryl)methyl]piperazine (J), for example, N-[2-(2-methylindol-3-yl)ethyl]-N′-[bis(4fluorophenyl)methyl]piperazine.
  • Example 6 provides the detailed procedure for this route.
  • a cinnamic acid (Q) may be reacted with lithium aluminum hydride and thionyl chloride, as previously described, to form a substituted allyl chloride (S).
  • the allyl chloride (S) is then reacted with the appropriate N-[bis(substituted)methyl]-piperazine (F) under basic conditions to form the targeted N-[(substituted)-alkenyl]-N′-[bis(substituted)methyl]piperazine (T).
  • Example 3 provides the detailed procedure for this route.
  • the reaction mixture was then cooled to 0° C., neutralized with aqueous saturated sodium bicarbonate solution, and extracted with two portions of diethyl ether. The combined extracts were washed with an aqueous saturated sodium chloride solution and dried with sodium sulfate, yielding 0.6 gram of crude material.
  • the crude material was purified by preparative TLC. Elution was accomplished with 3:2 ethyl acetate: methylene chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 0.4 gram of N-(4-chloroindol-3-ylmethyl)-N′-[(4-chlorophenyl)(2-chlorophenyl)methyl]piperazine.
  • the NMR spectrum was consistent with the proposed structure.
  • reaction mixture was cooled to ambient temperature, where it stirred for about 18 hours.
  • the reaction mixture was then poured into 50 mL of aqueous saturated sodium bicarbonate solution and then extracted with three 50 mL portions of diethyl ether.
  • the combined extracts were washed with 75 mL of aqueous saturated sodium chloride solution, dried over magnesium sulfate, and filtered.
  • the filtrate was concentrated under reduced pressure, yielding a crude oil, which was subjected to column chromatography on silica gel. Elution was accomplished with 1:1 ethyl acetate:heptane.
  • reaction mixture Upon completion of the addition the reaction mixture was allowed to warm to ambient temperature, where it stirred for about 18 hours, after which the reaction mixture was poured into a mixture of diethyl ether and aqueous 5% sodium hydroxide. The ether layer was separated and washed with water and then with an aqueous saturated sodium chloride solution. The organic layer was dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to an oil, which was subjected to column chromatography on silica gel. Elution was accomplished with pure hexane, followed by diethyl ether/hexane mixtures and then pure diethyl ether.
  • This compound was prepared in the manner of Example 3, with 0.63 gram (0.002 mole) of bis(4-cyanophenyl)methyl chloride, 0.86 gram (0.010 mole) of piperazine, and 1.4 mL (0.010 mole) of triethylamine in 20 mL of dimethyl sulfoxide as reagents and 0.1 gram (0.0005 mole) of sodium iodide as catalyst.
  • This procedure differed in that triethylamine was used, rather the N,N-diisopropylethylamine, and the reaction mixture was stirred at ambient temperature for about 48 hours rather than at 50-60° C. for about 18 hours.
  • the yield of N′-[bis(4-cyanophenyl)methyl]piperazine was 0.4 gram.
  • the NMR spectrum was consistent with the proposed structure.
  • the hydrochloric acid extracts were made basic with solid sodium bicarbonate and then extracted with two 25 mL portions of methylene chloride. The combined extracts were washed with one 25 mL portion of water, dried with sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, yielding 0.4 gram of a brown liquid, which was subjected to column chromatography on silica gel. Elution was accomplished with pure methylene chloride, followed by 1:9 diethyl ether:methylene chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 0.2 gram of a white solid. The white solid was purified by column chromatography on alumina with diethyl ether as the eluant.
  • N,N-dimethylformamide 2 drops, was added to a stirred mixture of 5.0 grams (0.026 mole) of 2-methylindole-3-acetic acid in 125 mL of diethyl ether. The solution was then cooled to 0° C., and 2.5 mL (0.029 mole) of oxalyl chloride was slowly added. Upon completion of the addition the reaction mixture was warmed to ambient temperature during 30 minutes, where it stirred for 1.5 hours, after which the reaction mixture was concentrated under reduced pressure to a residue. The residue was taken up in 30 mL of tetrahydrofuran and then divided into two 15 mL portions. Each 15 mL portion contained about 0.013 mole of 2-methylindol-3-ylacetyl chloride.
  • This compound was prepared by a Grignard reaction in which 45.0 grams (0.2 mole) of 4-bromobenzotrifluoride, 5.0 grams (0.22 mole) of magnesium, and 34.8 grams (0.20 mole) of 4-(trifluoromethyl)benzaldehyde were the reagents, and 1000 mL of diethyl ether was the solvent. The yield of bis(4-trifluoromethylphenyl)methanol was 37.0 grams.
  • This compound was prepared in the manner of Step B, Example 1, with 37.0 grams (0.115 mole) of bis(4-trifluoromethylphenyl)methanol, 27.3 grams (0.231 mole) of thionyl chloride, three drops of N,N-dimethylformamide as reagents, and 200 mL of methylene chloride as solvent. The yield of bis(4-trifluoromethylphenyl)methyl chloride was 31.8 grams. The NMR spectrum was consistent with the proposed structure.
  • This compound was prepared in the manner of Step C, Example 1, with 31.8 grams (0.094 mole) of bis(4-trifluoromethylphenyl)methyl chloride, 15.8 grams (0.1 mole) of ethyl 1-piperazinecarboxylate, 12.9 grams (0.1 mole) of ethyl diisopropylamine, 12.4 grams (0.083 mole) of sodium iodide as reagents, and 250 mL of toluene as solvent.
  • the yield of N-(ethoxycarbonyl)-N′-[bis(4-trifluoromethylphenyl)methyl]piperazine was 17.9 grams.
  • the NMR spectrum was consistent with the proposed structure.
  • This compound was prepared in the manner of Step D, Example 1, with 17.9 grams (0.039 mole) of N-(ethoxycarbonyl)-N′-[bis(4-trifluoromethylphenyl)methyl]piperazine, 150 mL of tetrahydrofuran, 25 mL of ethanol, and 50 mL of aqueous 50% sodium hydroxide as reagents. The yield of N-[bis-(4-trifluoromethylphenyl)methyl]piperazine 11.3 grams. The NMR spectrum was consistent with the proposed structure.
  • This compound was prepared in the manner of Example 6, with 0.81 gram (0.002 mole) of N-[bis(4-trifluoromethylphenyl)methyl]piperazine, 0.59 gram (0.002 mole) of 4-[1-(2-fluoroethyl)-1,2,3,5-(1H)-tetrazol-4-yl]benzyl bromide, 0.81 gram (0.006 mole) of N,N-diisopropylethylamine as reagents, and 25 mL of dimethyl sulfoxide as solvent.
  • the reaction mixture was cooled to ambient temperature, and 500 mL of water was added.
  • the organic and aqueous layers were separated.
  • the aqueous layer was basified with aqueous 10% sodium hydroxide and extracted with two 400 mL portions of diethyl ether.
  • the ether extracts were combined and washed with one 100 mL portion of aqueous 5% sodium hydroxide, followed by one 100 mL portion of aqueous 10% lithium chloride.
  • the organic layer and extracts were combined, dried with sodium sulfate, and filtered.
  • the filtrate was concentrated under reduced pressure to yield a residue, which was subjected to column chromatography on silica gel. Elution was accomplished with 15-20% acetone in petroleum ether mixtures.
  • the product-containing fractions were combined and concentrated under reduced pressure, yielding 13.5 grams of 4-(pyrid-2-yloxy)benzaldehyde.
  • the NMR spectrum was consistent with the proposed structure.
  • This compound was prepared in the manner of Step A, Example 1, with 1.87 grams ( 0.052 mole) of sodium borohydride, 13.5 grams (0.068 moles) of 4-(pyrid-2-yloxy)benzaldehyde as reagents, and 200mL of ethanol as solvent. The yield of 4-(pyrid-2-yloxy)benzyl alcohol was 13.0 grams. The NMR spectrum was consistent with the proposed structure.
  • This compound was prepared in the manner of Step B, Example 1, with 1.0 mL (0.012 mole) of pyrdine, 4.4 mL (0.06 mole) of thionyl chloride, 8.0 grams (0.04 mole) of 4-(pyrid-2-yloxy)benzyl alcohol as reagents, and 100 mL of anhydrous methylene chloride.
  • the yield of 4-(pyrid-2-yloxy)benzyl chloride was 0.66 grams.
  • the NMR spectrum was consistent with the proposed structure.
  • This compound was prepared in the manner of Example 3, with 1.15 grams (0.003 mole) of N-[bis(4-trifluoromethylphenyl)methyl]piperazine, 0.66 gram (0.003 mole) of 4-(pyrid-2-yloxy)benzyl chloride, 1.3 grams (0.01 mole) of N,N-diisopropylethylamine in 10 mL of dimethyl sulfoxide as reagents and 0.1 gram (0.0005 mole) of sodium iodide as catalyst..
  • the yield of N-[4-(pyrid-2-yloxy)phenylmethyl]-N′-[bis(4-trifluoromethylphenyl)methyl]-piperazine was 0.75 gram.
  • the NMR spectrum was consistent with the proposed structure.
  • the N-heterocyclylalkyl- or N-[(polycyclyl)alkyl]-N′-substituted piperazine derivatives of the present invention were incorporated into an artificial diet for evaluation of insecticidal activity against the tobacco budworm ( Heliothis virescens [Fabricius]) in the following manner.
  • Stock solutions of the test chemical in dimethyl sulfoxide were prepared for each rate of application.
  • One hundred microliters of each of the stock solutions was manually stirred into 50 mL of a molten (65-70° C.) wheat germ-based artificial diet.
  • the 50 mL of molten diet containing the test chemical was poured evenly into twenty wells in the outer four rows of a twenty-five well, five row plastic tray.
  • Each well in the tray was about 1 cm in depth, with an opening of 3 cm by 4 cm at the lip.
  • Molten diet containing only dimethylsulfoxide at the levels used in the test chemical-treated diet was poured into the five wells in the third row of the tray.
  • Each tray therefore contained one test chemical at a single rate of application, together with an untreated control.
  • the rates of application expressed as the negative log of the molar concentration, and the corresponding concentrations of the stock solution prepared for each rate are shown below:
  • Single second instar tobacco budworm larvae were placed in each well. The larvae were selected at a stage of growth at which they uniformly weigh about 5 mg each. Upon completion of infestation, a sheet of clear plastic was heat-sealed over the top of the tray using a common household flat iron. The trays were held at 25° C. at 60% relative humidity for five days in a growth chamber. Lighting was set at 14 hours of light and 10 hours of darkness. After the 5-day exposure period, mortality counts were taken, and the surviving insects were weighed. From the weights of the surviving insects that fed on the treated diet as compared to those insects that fed on the untreated diet, the percent growth inhibition caused by each test chemical was determined.
  • the compounds of the present invention caused significant inhibition of the growth of the tobacco budworm.
  • the most efficacious compounds were 38, 146, 147, 148, 150, and 151.
  • the data from the diet test are given in Table 3.
  • N-heterocyclylalkyl- or N-[(polycyclyl)alkyl]-N′-substituted piperazines derivatives causing high growth inhibition in the diet test were also tested for insecticidal activity in foliar evaluations against the tobacco budworm.
  • test plants were also observed for phytotoxicity and for reduction of feeding damage as compared to an untreated control.
  • the active compounds of the invention are formulated into insecticidal compositions by admixture in insecticidally effective amount with adjuvants and carriers normally employed in the art for facilitating the dispersion of active ingredients for the particular utility desired, recognizing the fact that the formulation and mode of application of a toxicant may affect the activity of the material in a given application.
  • the present insecticidal compounds may be formulated as granules of relatively large particle size, as water-soluble or water-dispersible granules, as powdery dusts, as wettable powders, as emulsifiable concentrates, as solutions, or as any of several other known types of formulations, depending on the desired mode of application.
  • insecticidal compositions may be applied either as water-diluted sprays, or dusts, or granules to the areas in which insect control is desired. These formulations may contain as little as 0.1%, 0.2% or 0.5% to as much as 95% or more by weight of active ingredient.
  • Dusts are free flowing admixtures of the active ingredients with finely divided solids such as talc, natural clays, kieselguhr, flours such as walnut shell and cottonseed flours, and other organic and inorganic solids which act as dispersants and carriers for the toxicant; these finely divided solids have an average particle size of less than about 50 microns.
  • a typical dust formulation useful herein is one containing 1.0 part or less of the insecticidal compound and 99.0 parts of talc.
  • Wettable powders are in the form of finely divided particles which disperse readily in water or other dispersant.
  • the wettable powder is ultimately applied to the locus where insect control is desired either as a dry dust or as an emulsion in water or other liquid.
  • Typical carriers for wettable powders include Fuller's earth, kaolin clays, silicas, and other highly absorbent, readily wet, inorganic diluents. Wettable powders normally are prepared to contain about 5-80% of active ingredient, depending on the absorbency of the carrier, and usually also contain a small amount of a wetting, dispersing, or emulsifying agent to facilitate dispersion.
  • a useful wettable powder formulation contains 80.8 parts of the insecticidal compound, 17.9 parts of Palmetto clay, and 1.0 part of sodium lignosulfonate and 0.3 part of sulfonated aliphatic polyester as wetting agents.
  • ECs emulsifiable concentrates
  • ECs emulsifiable concentrates
  • ECs emulsifiable concentrates
  • these concentrates are dispersed in water or other liquid carrier, and normally applied as a spray to the area to be treated.
  • the percentage by weight of the essential active ingredient may vary according to the manner in which the composition is to be applied, but in general comprises 0.5 to 95% of active ingredient by weight of the insecticidal composition.
  • Flowable formulations are similar to ECs except that the active ingredient is suspended in a liquid carrier, generally water.
  • Flowables like ECs, may include a small amount of a surfactant, and contain active ingredient in the range of 0.5 to 95%, frequently from 10 to 50%, by weight of the composition.
  • flowables may be diluted in water or other liquid vehicle, and are normally applied as a spray to the area to be treated.
  • Typical wetting, dispersing, or emulsifying agents used in agricultural formulations include, but are not limited to, the alkyl and alkylaryl sulfonates and sulfates and their sodium salts; alkylaryl polyether alcohols; sulfated higher alcohols; polyethylene oxides; sulfonated animal and vegetable oils; sulfonated petroleum oils; fatty acid esters of polyhydric alcohols and the ethylene oxide addition products of such esters; and the addition product of long-chain mercaptans and ethylene oxide.
  • alkylaryl polyether alcohols sulfated higher alcohols
  • polyethylene oxides polyethylene oxides
  • sulfonated animal and vegetable oils sulfonated petroleum oils
  • fatty acid esters of polyhydric alcohols and the ethylene oxide addition products of such esters and the addition product of long-chain mercaptans and ethylene oxide.
  • the surface-active agents when used, normally comprise from 1 to 15% by weight of the composition.
  • compositions include suspensions of the active ingredient in a relatively non-volatile solvent such as water, corn oil, kerosene, propylene glycol, or other suitable solvents.
  • Still other useful formulations for insecticidal applications include simple solutions of the active ingredient in a solvent in which it is completely soluble at the desired concentration, such as acetone, alkylated naphthalenes, xylene, or other organic solvents.
  • Granular formulations, wherein the toxicant is carried on relatively coarse particles, are of particular utility for aerial distribution or for penetration of cover crop canopy.
  • Pressurized sprays, typically aerosols wherein the active ingredient is dispersed in finely divided form as a result of vaporization of a low boiling dispersant solvent carrier, such as carbon dioxide, propane, or butane, may also be used.
  • Water-soluble or water-dispersible granules are also useful formulations for insecticidal application of the present compounds.
  • Such granular formulations are free-flowing, non-dusty, and readily water-soluble or water-miscible.
  • the soluble or dispersible granular formulations described in U.S. Pat. No. 3,920,442 are useful herein with the present insecticidal compounds.
  • the granular formulations, emulsifiable concentrates, flowable concentrates, solutions, etc. may be diluted with water to give a concentration of active ingredient in the range of say 0.1% or 0.2% to 1.5% or 2%.
  • the active insecticidal compounds of this invention may be formulated and/or applied with other insecticides, fungicides, nematicides, plant growth regulators, fertilizers, or other agricultural chemicals.
  • an effective amount and concentration of the active compound is applied to the locus where control is desired.
  • the locus may be, e.g., the insects themselves, plants upon which the insects feed, or the insect habitat.
  • the composition of the active compound may be applied to and optionally incorporated into the soil.
  • the effective amount may be as low as, e.g. about 10 to 500 g/ha, preferably about 100 to 250 g/ha.
  • R 3 R 4 D E G 44 4-Cl-Ph 4-Cl-Ph 4-F 5-Cl H 45 4-Cl-Ph 4-Cl-Ph 4-F 5-CH 3 H 46 4-Cl-Ph 4-Cl-Ph 4-CH 3 5-F H 47 4-Cl-Ph 4-Cl-Ph 4-F 6-F H 48 4-Cl-Ph 4-Cl-Ph 4-F 6-F 5-OCH 3 49 4-Cl-Ph 4-Cl-Ph 4-OCH 3 5-OCH 3 H 50 4-Cl-Ph 4-Cl-Ph 4-C(O)CH 3 H H 51 4-Cl-Ph 4-Cl-Ph 4-C(O)OCH(CH 3 ) 2 H H H
  • R is FIII, R 1 is 3-R 2 , U is CHZ, E, G, and J are H, is H, Ph is phenyl Cpd.
  • R 1 is 3-R 2 , U is (CH 2 ) 2 , D, E, G and J are H, m and n are 2 Cpd. R Cpd. R 66 68 67 69 Formula I U is (CH 2 ) 2 , J is H, m and n are 2, Ph is phenyl Cpd.
  • R R 1 R 3 R 4 109 FIII 4-F-Ph 4-F-Ph 110 FIII Ph Ph 111 FIII 4-F-Ph 4-F-Ph Formula I U is CH 2 , m and n are 2, Ph is phenyl Cpd.
  • R R 1 R 3 R 4 112 FIII 4-F-Ph 4-F-Ph 113 FIII 4-F-Ph 4-F-Ph 114 FIII Ph Ph Formula I U is —CH 2 —CH ⁇ CH—, m and n are 2, Ph is phenyl Cpd.
  • R R 1 R 3 R 4 120 FIII 4-Cl-Ph 4-Cl-Ph 121 FIII 4-Cl-Ph 4-Cl-Ph 122 FIII Ph 4-Cl-Ph Formula I U is CH 2 , m and n are 2, Ph is phenyl Cpd.
  • R R 1 R 3 R 4 123 FIII 4-Cl-Ph 4-Cl-Ph 124 FIII 4-Cl-Ph 4-Cl-Ph Formula II U is CH 2 , A and B are H, Ph is phenyl Cpd.
  • R 1 R 3 R 4 A B 185 4-OCH 3 -Ph 4-OCF 3 -Ph 4-OCF 3 -Ph 1-( ⁇ O) 4-( ⁇ O) (Isomer 1) 186 4-OCH 3 -Ph 4-OCF 3 -Ph 4-OCF 3 -Ph 1-( ⁇ O) 4-( ⁇ O) (Isomer 2)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of the following structure are disclosed as effective insecticides:
Figure USH0002007-20011204-C00001
in which: A and B are independently lower alkyl; U is lower alkylidene, lower alkenylidene, or CH—Z, where Z is hydrogen, lower alkyl, lower cycloalkyl, or phenyl; R is phenyl or a dibenzocyclo(C5-8)alkyl, each optionally substituted, or
Figure USH0002007-20011204-C00002
where R3 and R4 are independently selected from phenyl, optionally substituted with, halogen, lower alkyl, lower haloalkyl, lower alkoxy, lower haloalkoxy, lower alkenyl, or phenyl; R1 is selected from a variety of substituents, including 3-R2, where R2 is
Figure USH0002007-20011204-C00003
where D, E, and G are hydrogen, hydroxy, halogen, cyano, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy, nitro, lower haloalkylsuffonyloxy, lower alkylcarboxylato, lower alkylcarbonylamino, lower alkylcarbonyl, lower alkoxycarbonyl, arylcarbonylamino; D and E taken together may form the group —O(CH2)O—; J is hydrogen or lower alkyl; m is 2 or 3, n is 1, 2, or 3; and halogen is chlorine, bromine, or fluorine.

Description

This application claims benefit of Provisional No. 60/010,237 filed Jan. 19, 1996.
The present invention relates to methods for controlling insects. In particular, it relates to control by application of certain N-heterocyclylalkyl- or N-[(polycyclyl)alkyl]N′-substituted piperazine derivatives to locus where insect control is needed. While not all compounds of the class are novel, the use of the compounds of the invention as insecticides is heretofore unknown.
It has now been found that compounds of the following structure and their agriculturally acceptable salts are active as insecticides:
Figure USH0002007-20011204-C00004
where:
A and B are independently selected from lower alkyl;
U is selected from lower alkyl, lower alkenyl, CH—Z, where Z is independently selected from hydrogen, lower alkyl, lower cycloalkyl, and phenyl;
R is selected from phenyl, optionally substituted with halogen, lower alkyl, lower alkoxy, phenyl, or phenoxy, and from polycyclyl, optionally substituted with halogen, lower alkyl, or lower alkoxy, where polycyclyl is a dibenzocyclo(C5-8)alkyl; and
Figure USH0002007-20011204-C00005
where R3 and R4 are independently selected from phenyl, optionally substituted with halogen, lower alky, lower haloalkyl, lower alkoxy, lower haloalkoxy, lower alkenyl, or phenyl;
R1 is phenyl, naphthyl, tetrazolylphenyl, phenylcyclopropyl, phenoxyphenyl, benzyloxyphenyl, pyridylphenyl, pyridyloxyphenyl, thiadiazolyloxyphenyl, benzothienyl, benzimidazolyl, indolyl, pyrrolyl, or quinolyl, each optionally substituted with halogen, cyano, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy, amino, lower dialkylamino, nitro, lower haloalkylsulfonyloxy, lower alkylcarbonyloxy, lower alkylcarbonylamino, lower alkoxycarbonyl, lower alkoxyalkoxycarbonyl, lower cycloalkylalkoxycarbonyl, lower alkoxyalkylalkoxycarbonyl, lower alkoxycarbonylamino, alkoxythiocarbonylamino, lower alkyldithiocarbonylamino, lower dialkyldioxolylalkoxycarbonylamino, or halophenylamino; or lower alkyl substituted with any one of the foregoing cyclic R1 groups; or 3-R2, where R2 is
Figure USH0002007-20011204-C00006
where D, E, and G are independently selected from hydrogen, halogen, cyano, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy, nitro, lower haloalkylsulfonyloxy, lower alkylcarbonyloxy, lower alkylcarbonylamino, arylcarbonylamino, lower alkylcarbonyl, lower alkoxycarbonyl, or D and E taken together may form the group —O(CH2)O—, and J is hydrogen or lower alkyl;
m is 2 or 3 and n is 1, 2, or 3; and
halogen is chlorine, fluorine, or bromine, lower means having from 1 to 6 carbon atoms and any aliphatic chain of three or more carbons may be straight or branched.
Preferred compounds are those in which
U is CH2;
R is
Figure USH0002007-20011204-C00007
where R3 and R4 are independently selected from chlorophenyl, fluorophenyl, methylphenyl, trifluoromethylphenyl, methoxyphenyl, and trifluoromethoxyphenyl;
R1 is phenyl, tetrazolylphenyl, pyridylphenyl, pyridyloxyphenyl; each optionally substituted with halogen, cyano, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy, amino, lower dialkylamino, lower alkylcarbonyloxy, lower alkylcarbonylamino, lower alkoxycarbonyl, lower alkoxyalkoxycarbonyl, lower cycloalkylalkoxycarbonyl, lower alkoxyalkylalkoxycarbonyl, or lower alkoxycarbonylamino; or lower alkyl substituted with any one of the foregoing cyclic R1 groups; or 3-R2, where R2 is
Figure USH0002007-20011204-C00008
where D is hydrogen, hydroxy, chloro, fluoro, methyl, methoxy, or phenylcarbonylamino; E and G are independently selected from hydrogen, chloro, fluoro, methyl, and methoxy, with the proviso that when R1 is lower dialkylaminophenyl, R3 and R4 are each trifluoromethoxyphenyl;
m and n are 2; and
halogen is chlorine or fluorine, for aliphatic groups lower means having from 1 to 3 carbon atoms and for alicyclic groups lower means having 3 to 6 carbons.
Particularly preferred are those compounds in which
U is CH2;
R is
Figure USH0002007-20011204-C00009
where R3 and R4 are independently selected from 4-chlorophenyl, 4-fluorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, and 4-trifluoromethoxyphenyl;
R1 is phenyl substituted in the 4-position with lower dialkylamino, lower alkoxycarbonylamino, tetrazolyl, pyridyl, or pyridyloxy; each tetrazolyl or pyridyl group optionally substituted with halogen, cyano, lower alkyl, lower haloalkyl, or lower alkoxy; or 3-R2, where R2 is
Figure USH0002007-20011204-C00010
where D is hydrogen, 4-chloro, 4-fluoro, 4-hydroxy, or 4-phenylcarbonylamino; E is hydrogen, 5-chloro, 5-methyl, or 6-fluoro; G is hydrogen or 5-methoxy;
m and n are 2; and
halogen is chlorine or fluorine, for aliphatic groups lower means having from 1 to 3 carbon atoms and for alicyclic groups lower means having 3 to 6 carbons.
The N-heterocyclylalkyl- or N-[(polycyclyl)alkyl]-N′-substituted piperazine derivatives of the present invention were prepared by methods known to one skilled in the art. A number of synthesis routes were employed in obtaining the targeted compounds.
Synthesis of the piperazine starting materials are depicted in Schema 1. Various R group intermediates were prepared by first reacting an aryl Grignard reagent (A) with a substituted aldehyde (B), for example, 2,4-dichlorobenzaldehyde, to afford the corresponding (substituted diaryl)methanol (C), for example, (2-chlorophenyl)(4-chlorophenyl)methanol. C can also be prepared by reacting substituted benzophenones (D) with sodium borohydride. The diaryl methanol (C) is then treated with thionyl chloride affording a (substituted diaryl)methyl chloride (E), for example, (2-chlorophenyl)(4-chlorophenyl)methyl chloride. The so-prepared diaryl methyl chloride (E) can then be reacted with piperazine to form the N-[(substituted diaryl)methyl]piperazine (F). The piperazine (F) can be reacted with an appropriate halide (G), affording the targeted N-(substituted alkyl)-N′-[(substituted diaryl)methyl]piperazine (H), for example, N-(4-chloroindol-3-yl-methyl)-N′-[(4-chlorophenyl)(2-chlorophenyl)methyl)piperazine. Alternatively, a substituted indole (I) capable of undergoing a Mannich-type reaction is condensed with formaldehyde and the N-substituted piperazine in dioxane and acetic acid to afford the targeted N-(substituted alkyl)-N′-(R-substituted)-piperazine (J), for example, N-(benzo[β]ythien-3-ylmethyl)-N′-[bis(4-chlorophenyl)methyl]piperazine. Example 1 provides the detailed procedure for this route.
As depicted by Schema 2, those compounds in which Z is other than hydrogen are prepared by first reacting a substituted indole (I) with phosphorus oxychloride and N,N-dimethylformamide, affording the corresponding substituted aldehyde (K). K is in turn condensed with N-[(substituted diaryl)-methyl]piperazine (F) to form the imine and then reacted with the appropriate alkyl or aryl magnesium halide, for example, phenyl magnesium chloride, affording the targeted N-[(alkyl)(substituted indole)alkyl]- or N-[(aryl)(substituted heterocyclyl)alkyl]-N′-[(substituted diaryl)methyl]piperazine (L), for example, N-[(phenyl)(4-chloroindol-3-yl)methyl]-N′-[bis(4-chlorophenyl)-methyl]piperazine. The substituted indole (I) can also be reacted with an aldehyde and N-[(substituted diaryl)methyl]piperazine (F) under acidic conditions, affording the targeted N-[(alkyl)(substituted heterocyclyl)alkyl]- or N-[(aryl)(substituted heterocyclyl)alkyl]-N′-[(substituted diaryl)methyl]piperazine (L). Examples 2 and 4 provide detailed procedures for this route.
Compounds having the F structure are particularly useful intermediates. The compound with R3 and R4 each trifluoromethoxyphenyl, i.e., N-[bis(4-trifluoromethoxyphenyl)methyl]piperazine, is thought to be novel and has the following NMR spectrum, proton assignment in ppm in CDCl3: 2.41 (m, 4H); 2.54 (d of m, 2H); 2.98 (m, 2H); 3.39 (t, 1H); 7.15 (d, 4H); 7.40 (d 4H).
At this point an N-[(substituted diaryl)methyl]piperazine (F) can be reacted with an appropriately substituted aldehyde for example, 4-dimethylaminobenzaldehyde, under acidic conditions and at 100 ° C., affords the targeted N-(substituted alkyl)-N′-[(substituted diaryl)methyl]piperazine (M). Example 5 provides the detailed procedure for this route.
Schema 3 outlines routes to compounds where the tether U is varied. An acid chloride (N) is derivatized with an appropriate N-[(substituted diaryl)-methyl]piperazine (E), affording the targeted N-[(substituted)alkylcarbonyl]-N′-[(substituted diaryl)methyl]piperazine (O). The piperazine (O) can also be prepared by derivatizing a substituted carboxylic acid (P), for example, 2-methyl-3-indoleacetic acid, with an appropriate N-[(substituted diaryl)methyl]-piperazine (F). The piperazine (O) is then converted to the targeted N-(substituted alkyl)-N′-[(substituted diaryl)methyl]piperazine (J), for example, N-[2-(2-methylindol-3-yl)ethyl]-N′-[bis(4fluorophenyl)methyl]piperazine. Example 6 provides the detailed procedure for this route.
To obtain compounds in which U is a lower alkenyl, a cinnamic acid (Q) may be reacted with lithium aluminum hydride and thionyl chloride, as previously described, to form a substituted allyl chloride (S). The allyl chloride (S) is then reacted with the appropriate N-[bis(substituted)methyl]-piperazine (F) under basic conditions to form the targeted N-[(substituted)-alkenyl]-N′-[bis(substituted)methyl]piperazine (T). Example 3 provides the detailed procedure for this route.
Figure USH0002007-20011204-C00011
Figure USH0002007-20011204-C00012
Figure USH0002007-20011204-C00013
EXAMPLE 1 Synthesis of N-(4-Chloroindol-3-ylmethyl)-N′-[(4-Chlorophenyl)(2-Chlorophenyl)Methyl]-Piperazine (Compound 19)
Step A Synthesis of (2-chlorophenyl)(4-chlorophenyl)methanol as an intermediate
Under a nitrogen atmosphere, 1.7 grams ( 0.044 mole) of sodium borohydride pellets was added to 100 ml of stirred ethanol. To this was added 10.0 grams (0.040 moles) of 2,4′-dichlorobenzophenone in one portion. Upon completion of the addition the reaction mixture was stirred at ambient temperature for about 18 hours. After this time the ethanol was removed under reduced pressure, and the resulting residue was taken up in 250 mL of aqueous 5% sodium hydroxide solution. The solution was extracted with two 100 mL portions of diethyl ether. The combined ether extracts were washed with aqueous saturated sodium chloride solution. The organic layer was filtered and the filtrate concentrated under reduced pressure, yielding 9.5 grams of (2-chlorophenyl)(4-chlorophenyl)methanol. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of (2-chlorophenyl)(4-chlorophenyl)methyl chloride as an intermediate
A stirred solution of 9.0 grams (0.036 mole) of (2-chlorophenyl)(4-chlorophenyl)methanol in 90 mL of chloroform was cooled to 0° C., and 5.3 mL (0.072 mole) of thionyl chloride was added. Upon completion of the addition the reaction mixture was allowed to warm to ambient temperature, where it stirred for about 18 hours. After this time the reaction mixture was filtered and concentrated under reduced pressure. The filtrate was taken up in hexane and subjected to column chromatography on silica gel with hexane as eluant. The product-containing fractions were combined and concentrated under reduced pressure, yielding 10.0 grams of (2-chlorophenyl)(4-chlorophenyl)methyl chloride. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of N-(ethoxycarbonyl)-N′-[(2-chlorophenyl)(4-chloro phenyl)methyl]piperazine as an intermediate
A stirred solution of 2.5 grams (0.009 mole) of (2-chlorophenyl)(4-chlorophenyl)methyl chloride, 1.6 grams (0.010 mole) of ethyl 1-piperazine-carboxylate, 1.4 mL (0.010 mole) of triethylamine, and 1.2 grams (0.008 mole) of sodium iodide in 25 mL of toluene was heated at reflux for about 18 hours. The resulting precipitate was collected by filtration. The filtrate was cooled to ambient temperature and 200 mL of aqueous saturated sodium bicarbonate solution was added to it. The mixture was extracted with two 100 mL portions of ethyl acetate. The combined ethyl acetate layers were washed with two 25 mL portions of an aqueous saturated sodium chloride solution. The organic layer was dried with sodium sulfate and concentrated under reduced pressure, yielding 3.2 grams of crude material. The crude material was subjected to column chromatography on silica gel with 50-25% hexane in methylene chloride, followed by pure methylene chloride, as eluants. The product-containing fractions were combined and concentrated under reduced pressure, yielding 1.0 gram of N-(ethoxycarbonyl)-N′-[(2-chlorophenyl)(4-chlorophenyl)methyl]piperazine. The NMR spectrum was consistent with the proposed structure.
Step D Synthesis of N′-[(2-chlorophenyl)(4-chlorophenyl)methyl]piperazine as an intermediate
To a stirred solution of 0.9 gram (0.002 mole) of N-(ethoxycarbonyl)-N′-[(2-chlorophenyl)(4-chlorophenyl)methyl]piperazine in 10 mL of tetrahydrofuran was added 10 mL of methanol and 10 mL of aqueous 50% sodium hydroxide. Upon completion of the addition the reaction mixture was warmed to 80° C., where it stirred for 24 hours. At the end of this time the reaction mixture was concentrated under reduced pressure. The concentrate was dissolved in chloroform, and the solution was stirred for 40 minutes. The resulting precipitate was collected by filtration. The filtrate was concentrated under reduced pressure, yielding 0.6 gram of crude material. The crude material was purified by preparative thin layer chromatography (TLC). Elution was accomplished with 1:1 acetone: methanol. The product-containing fractions were combined and concentrated under reduced pressure, yielding 0.4 gram of N′-[(2-chlorophenyl)(4-chlorophenyl)-methyl]piperazine. The NMR spectrum was consistent with the proposed structure.
Step E Synthesis of N-(4-chloroindol-3-ylmethyl)-N′-[(4-chlorophenyl) (2-chlorophenyl)methyl]piperazine (Compound 19)
A stirred solution of 0.4 gram (0.001 mole) of N′-[(2-chlorophenyl)(4-chlorophenyl)methyl]piperazine in 1 mL of dioxane was cooled to 0° C. To this was added 2 mL of glacial acetic acid followed by 0.14 mL of 37% aqueous formaldehyde. A solution of 0.2 gram (0.001 mole) of 4-chloroindole in 1 mL of dioxane was then slowly added. Upon completion of the addition the reaction mixture was warmed to ambient temperature where it stirred for five hours. The reaction mixture was then cooled to 0° C., neutralized with aqueous saturated sodium bicarbonate solution, and extracted with two portions of diethyl ether. The combined extracts were washed with an aqueous saturated sodium chloride solution and dried with sodium sulfate, yielding 0.6 gram of crude material. The crude material was purified by preparative TLC. Elution was accomplished with 3:2 ethyl acetate: methylene chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 0.4 gram of N-(4-chloroindol-3-ylmethyl)-N′-[(4-chlorophenyl)(2-chlorophenyl)methyl]piperazine. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 2 Synthesis of N-[(Phenyl)(4-Chloroindol-3-yl)Methyl]-N′-[bis(4-Chlorophenyl)Methyl]Piperazine (Compound 59)
Step A Synthesis of 4-chloro-3-formylindole as an intermediate
During a period of five minutes 2.3 grams (0.015 mole) of phosphorus oxychloride was added dropwise to 10 mL of N,N-dimethylformamide. The solution was stirred for 30 minutes and then cooled in an ice bath. To this was added dropwise a solution of 2.0 grams (0.013 mole) of 4-chloroindole in 3 mL of N,N-dimethylformamide. Upon completion of the addition the ice bath was removed, and the reaction mixture was warmed to ambient tempeature, where it stirred for 1.5 hours. After this time the reaction mixture was warmed to 40° C., where it was stirred for 30 minutes, and then poured onto 50 grams of ice. A solution of 5.9 grams (0.146 mole) of sodium hydroxide in 20 mL of water was added during a 2-3 minute period, after which the mixture was heated to reflux and then cooled to ambient temperature. The cooled mixture was poured into 500 mL of water, stirred at ambient temperature for about 18 hours, and then filtered to collect a solid that had precipitated. The solid was washed with three portions of water and then dissolved in ethyl acetate. The ethyl acetate solution was subjected to column chromatography on silica gel with 1:1 ethyl acetate:hexane as eluant. The product-containing fractions were combined and concentrated under reduced pressure, yielding 1.4 grams of 4-chloro-3-formylindole. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of N-(4-chloro-3H-indol-3-ylmethylenyl)-N′-[bis(4-chlorophenyl)methyl]piperazine as an intermediate
A stirred solution of 0.2 gram (0.001 mole) of 4-chloro-2-formylindole and 0.4 gram (0.001 mole) of N′-[bis(4-chlorophenyl)methyl]piperazine in 75 mL of toluene was heated at reflux for 16 hours using a Dean Stark trap. After this time the heat was removed, and the reaction mixture was concentrated under reduced pressure, yielding about 0.6 gram of solid N-(4-chloro-3H-indol-3-ylmethenyl)-N′-[bis(4-chlorophenyl)methyl]piperazine.
Step C Synthesis of N-[(phenyl)(4chloroindol-3-yl)methyl]-N′-[bis(4-chlorophenyl)methyl]piperazine (Compound 59)
A mixture of about 0.6 gram (0.001 mole) of N-(4-chloro-3H-indol-3-yl-methinyl)-N′-[bis(4-chlorophenyl)methyl]piperazine in 20 mL of tetrahydrofuran was stirred at ambient temperature, and 1.2 mL (0.002 mole) of 2M phenyl magnesium chloride (in tetrahydrofuran) was added dropwise during a 5 minute period. Upon completion of the addition the reaction mixture was stirred for 30 minutes at ambient temperature, then heated to 50-80° C., where it stirred for two hours. After this time the homogeneous reaction mixture was cooled to ambient temperature and poured into 200 mL of an aqueous saturated ammonium chloride solution. The resulting solution was then extracted with three 100 mL portions of ethyl acetate. The combined extracts were washed with two 100 mL portions of aqueous sodium chloride solution, dried with sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to a residue, which was subjected to column chromatography on silica gel. Elution was accomplished with 7:13 ethyl acetate:hexane. The product-containing fractions were combined and concentrated under reduced pressure, yielding 0.3 gram of N-[(phenyl)(4-chloroindol-3yl)methyl]-N′-[bis(4-chlorophenyl)methyl]piperazine, mp 100-105° C. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 3 Synthesis of N-[3-(4-Nitrophenyl)-2-Propenyl]-N′-[bis(4-Fluorophenyl)Methyl]Piperazine (Compound 108)
A solution of 0.5 gram (0.002 mole) of 3-(4-nitrophenyl)-2-propenyl chloride in 5 mL of dimethyl sulfoxide was added to a solution of 0.7 gram (0.002 mole) of N-[bis(4-fluorophenyl)methyl]piperazine in 10 mL of dimethyl sulfoxide. To this was added 0.1 gram (0.0005 mole) of sodium iodide as a catalyst. Upon completion of the addition 1.2 grams (0.010 mole) of N,N-diisopropylethylamine was added dropwise. To effect solution the reaction mixture was then warmed to 50-80° C., where it stirred for four hours . After this time the reaction mixture was cooled to ambient temperature, where it stirred for about 18 hours. The reaction mixture was then poured into 50 mL of aqueous saturated sodium bicarbonate solution and then extracted with three 50 mL portions of diethyl ether. The combined extracts were washed with 75 mL of aqueous saturated sodium chloride solution, dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, yielding a crude oil, which was subjected to column chromatography on silica gel. Elution was accomplished with 1:1 ethyl acetate:heptane. The product-containing fractions were combined and concentrated under reduced pressure, yielding 0.5 gram of of N-[3-(4-nitrophenyl)-2-propenyl]-N′-[bis(4-fluorophenyl)methyl]piperazine. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 4 Synthesis of N-[1-(Indol3-yl)Propyl]-N′-[(4-Chlorophenyl) (Phenyl)Methyl]Piperazine (Compound 54)
A solution of 2.0 grams (0.006 mole) of N-[(4-chlorophenyl)(phenyl)-methyl]piperazine and 0.5 mL (0.007 mole) of propionaldehyde in 8.0 mL of dioxane and 8.0 mL of glacial acetic acid was stirred and cooled in an ice bath. To this a solution of 0.7 gram (0.006 mole) of indole in 10.0 mL of dioxane was added dropwise during a 15 minute period. Upon completion of the addition the reaction mixture was allowed to warm to ambient temperature, where it stirred for about 18 hours, after which the reaction mixture was poured into a mixture of diethyl ether and aqueous 5% sodium hydroxide. The ether layer was separated and washed with water and then with an aqueous saturated sodium chloride solution. The organic layer was dried with magnesium sulfate and filtered. The filtrate was concentrated under reduced pressure to an oil, which was subjected to column chromatography on silica gel. Elution was accomplished with pure hexane, followed by diethyl ether/hexane mixtures and then pure diethyl ether. The product-containing fractions were combined and concentrated under reduced pressure, yielding 0.3 gram of N-[1-(indol-3yl)propyl]-N′-[(4chlorophenyl)-(phenyl)methyl]piperazine. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 5 Synthesis of N-(4-Dimethylaminophenylmethyl)-N′-[bis(4-Cyanophenyl)Methyl]Piperazine (Compound 118)
Step A Synthesis of N-t-butyl-4-bromobenzamide as an intermediate
Under a nitrogen atmosphere, 4.5 mL (0.043 mole) of t-butylamine was added to a solution of 7.7 grams (0.035 mole) of 4-bromobenzoyl chloride in 75 mL of tetrahydrofuran. To this was added dropwise 6.7 mL (0.048 mole) of triethylamine. Upon completion of the addition the reaction mixture was stirred at ambient temperature for about 18 hours, after which it was poured into 50 mL of water, and the organic layer was separated. The aqueous layer was extracted with one 50 mL portion of diethyl ether. The combined organic layer and extract were washed with two 25 mL portions of water, dried with sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, yielding 8.4 grams of N-t-butyl-4-bromobenzamide, mp 126-128° C. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of bis[4-(t-butylaminocarbonyl)phenyl]methanol as an intermediate
Under a nitrogen atmosphere, a stirred solution of 7.8 grams ( 0.030 mole) of N-t-butyl-4-bromobenzamide in 125 mL of tetrahydrofuran was cooled to −60° C., and 28 mL (0.063 mole) of 2M n-butyllithium in hexanes was added dropwise during a 30 minute period. Upon completion of the addition the reaction mixture was stirred at −60° C. for 1.5 hours, then a solution of 1.2 mL (0.015 mole) of ethyl formate in 25 mL of diethyl ether was added dropwise. The reaction mixture was stirred at −60° C. for an additional 1.5 hours, and 150 mL of aqueous saturated ammonium chloride solution was added dropwise, followed by 50 mL of methylene chloride and 50 mL of ethyl acetate, and then the mixture was warmed to ambient temperature. The organic layer was separated and washed with one 50 mL portion of water and one 50 mL portion of an aqueous saturated sodium chloride solution . The organic layer was dried with sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, yielding 2.9 grams. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of bis(4-cyanophenyl)methyl chloride as an intermediate
Under a nitrogen atmosphere, a stirred solution of 2.9 grams (0.008 mole) of bis[4-(t-butylaminocarbonyl)phenyl]methanol in 25 mL (0.0340 mole) of thionyl chloride was heated at reflux for five hours. After this time the reaction mixture was concentrated under reduced pressure, yielding a residue. The residue was dissolved in about 10 mL of toluene. The solution was again concentrated under reduced pressure, yielding a residue. This residue was again dissolved in about 10 mL of toluene, and the resulting solution was concentrated under reduced pressure, yielding 2.2 grams of a brown liquid. Methylene chloride was added to 1.0 gram of the liquid, and the resulting solution was filtered through a silica gel pad. The filtrate was washed with methylene chloride. The filtrate and wash were combined and concentrated under reduced pressure, yielding 0.7 gram of bis(4-cyano-phenyl)methyl chloride. The NMR spectrum was consistent with the proposed structure.
Step D Synthesis of N′-[bis(4-cyanophenyl)methyl]piperazine as an intermediate
This compound was prepared in the manner of Example 3, with 0.63 gram (0.002 mole) of bis(4-cyanophenyl)methyl chloride, 0.86 gram (0.010 mole) of piperazine, and 1.4 mL (0.010 mole) of triethylamine in 20 mL of dimethyl sulfoxide as reagents and 0.1 gram (0.0005 mole) of sodium iodide as catalyst. This procedure differed in that triethylamine was used, rather the N,N-diisopropylethylamine, and the reaction mixture was stirred at ambient temperature for about 48 hours rather than at 50-60° C. for about 18 hours. The yield of N′-[bis(4-cyanophenyl)methyl]piperazine was 0.4 gram. The NMR spectrum was consistent with the proposed structure.
Step E Synthesis of N-(4-dimethylaminophenylmethyl)-N′-[bis(4-cyanophenyl)methyl]piperazine (Compound 118)
A stirred solution of 0.4 gram (0.002 mole) of N-[bis(4-cyanophenyl)-methyl]piperazine and 0.2 gram (0.002 mole) of 4-dimethylaminobenzaldehyde was heated in an oil bath to 100° C., and then 0.1 mL (0.002 mole) of formic acid was added. Upon completion of the addition the reaction mixture was stirred at 100° C. for five hours, after which time it was cooled to ambient temperature, where it was stirred for about 18 hours. At the conclusion of this period 25 mL of methylene chloride was added to the reaction mixture, and the solution was extracted with two 20 mL portions of aqueous 10% hydrochloric acid. The hydrochloric acid extracts were made basic with solid sodium bicarbonate and then extracted with two 25 mL portions of methylene chloride. The combined extracts were washed with one 25 mL portion of water, dried with sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, yielding 0.4 gram of a brown liquid, which was subjected to column chromatography on silica gel. Elution was accomplished with pure methylene chloride, followed by 1:9 diethyl ether:methylene chloride. The product-containing fractions were combined and concentrated under reduced pressure, yielding 0.2 gram of a white solid. The white solid was purified by column chromatography on alumina with diethyl ether as the eluant. The product-containing fractions were combined and concentrated under reduced pressure, yielding 0.1 gram of N-(4-dimethylaminophenylmethyl)-N′-[bis(4-cyanophenyl)methyl]piperazine. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 6 Synthesis of N-(2-Methylindol-3-ylethyl)-N′-[bis(4-Fluorophenyl)Methyl]Piperazine (Compound 36)
Step A Synthesis of 2-methylindol-3-ylacetyl chloride as an intermediate
N,N-dimethylformamide, 2 drops, was added to a stirred mixture of 5.0 grams (0.026 mole) of 2-methylindole-3-acetic acid in 125 mL of diethyl ether. The solution was then cooled to 0° C., and 2.5 mL (0.029 mole) of oxalyl chloride was slowly added. Upon completion of the addition the reaction mixture was warmed to ambient temperature during 30 minutes, where it stirred for 1.5 hours, after which the reaction mixture was concentrated under reduced pressure to a residue. The residue was taken up in 30 mL of tetrahydrofuran and then divided into two 15 mL portions. Each 15 mL portion contained about 0.013 mole of 2-methylindol-3-ylacetyl chloride.
Step B Synthesis of N-(2-methylindol-3-ylacetyl)-N′-[bis(4-fluoro phenyl)methyl]piperazine as an intermediate
Under a nitrogen atmosphere a 15 mL solution of 2-methylindol-3-ylacetyl chloride (0.013 mole) in tetrahydrofuran was added to a stirred solution of 3.9 grams (0.014 mole) of N-[bis(4-fluorophenyl)methyl]piperazine and 1.1 mL (0.013 mole) of pyridine in 50 mL of dried tetrahydrofuran. Upon completion of the addition the reaction mixture was stirred at ambient temperature for about 18 hours, after which the reaction mixture was poured into a mixture of 200 mL of ethyl acetate and 100 mL of aqueous saturated sodium bicarbonate solution. The organic layer was separated and washed with one portion of a saturated sodium chloride solution, dried with sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to a solid, which was taken up in hexane. This solution was concentrated under reduced pressure, yielding 3.2 grams of N-(2-methylindol-3-ylacetyl)-N′-[bis(4-fluorophenyl)methyl]piperazine, mp 93-103° C. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of N-(2-methylindol-3-ylethyl)-N′-[bis(4-fluoro phenyl)methyl]piperazine (Compound 36)
A solution of 1.5 grams (0.003 mole) of N-(2-methylindol-3-ylacetyl)-N′-[bis(4-fluorophenyl)methyl]piperazine in 10.0 mL of anhydrous tetrahydrofuran was added to a stirred mixture of 0.4 gram (0.010 mole) of lithium aluminum hydride in 5.0 mL of anhydrous tetrahydrofuran. Upon completion of the addition the reaction mixture was heated to reflux, where it stirred for 2.5 hours. The reaction mixture was cooled to 0° C., and water was added, followed by 50 mL of aqueous 10% sodium hydroxide. The solution was warmed to ambient temperature and then extracted with ethyl acetate. The extract was dried with sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, yielding 0.7 gram of N-(2-methylindol-3-ylethyl)-N′-[bis(4-fluorophenyl)methyl]piperazine, mp 65-73° C. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 7 Synthesis of N-{4-[1-(2-Fluoroethyl)-1 ,2,3,5-(1H)-Tetrazol-4-yl]Phenylmethyl}-N′-[bis(4-Trifluoromethylphenyl)]-Piperazine (Compound 150)
Step A Synthesis of bis(4-trifluoromethylphenyl)methanol as an intermediate
This compound was prepared by a Grignard reaction in which 45.0 grams (0.2 mole) of 4-bromobenzotrifluoride, 5.0 grams (0.22 mole) of magnesium, and 34.8 grams (0.20 mole) of 4-(trifluoromethyl)benzaldehyde were the reagents, and 1000 mL of diethyl ether was the solvent. The yield of bis(4-trifluoromethylphenyl)methanol was 37.0 grams.
Step B Synthesis of bis(4-trifluoromethylphenyl)methyl chloride as an intermediate
This compound was prepared in the manner of Step B, Example 1, with 37.0 grams (0.115 mole) of bis(4-trifluoromethylphenyl)methanol, 27.3 grams (0.231 mole) of thionyl chloride, three drops of N,N-dimethylformamide as reagents, and 200 mL of methylene chloride as solvent. The yield of bis(4-trifluoromethylphenyl)methyl chloride was 31.8 grams. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of N-(ethoxycarbonyl)-N′-[bis(4-trifluoromethyl phenyl)methyl]piperazine as an intermediate
This compound was prepared in the manner of Step C, Example 1, with 31.8 grams (0.094 mole) of bis(4-trifluoromethylphenyl)methyl chloride, 15.8 grams (0.1 mole) of ethyl 1-piperazinecarboxylate, 12.9 grams (0.1 mole) of ethyl diisopropylamine, 12.4 grams (0.083 mole) of sodium iodide as reagents, and 250 mL of toluene as solvent. The yield of N-(ethoxycarbonyl)-N′-[bis(4-trifluoromethylphenyl)methyl]piperazine was 17.9 grams. The NMR spectrum was consistent with the proposed structure.
Step D Synthesis of N-[bis(4-trifluoromethylphenyl)methyl]piperazine as an intermediate
This compound was prepared in the manner of Step D, Example 1, with 17.9 grams (0.039 mole) of N-(ethoxycarbonyl)-N′-[bis(4-trifluoromethylphenyl)methyl]piperazine, 150 mL of tetrahydrofuran, 25 mL of ethanol, and 50 mL of aqueous 50% sodium hydroxide as reagents. The yield of N-[bis-(4-trifluoromethylphenyl)methyl]piperazine 11.3 grams. The NMR spectrum was consistent with the proposed structure.
Step E Synthesis of 4-(4-methylphenyl)-1,2,3,5-(1 H)-tetrazole as an intermediate
A stirred solution of 117 grams (1.0 mole) of 4-cyanotoluene, 65.0 grams (1.0 mole) of sodium azide, and 12.0 grams (0.224 mole) of ammonium chloride 800 mL of N,N-dimethylformamide was heated at 130° C. for three hours. After this time the reaction mixture was cooled and then poured into 800 mL of water and 400 mL of ice. The resulting mixture was acidified to pH 2 with 3N hydrochloric acid, and the resulting solid was collected by filtration. The solid was washed with hexane, triturated with 300 mL of methanol, and dried under reduced pressure to a constant weight, yielding 115 grams of 4-(4-methylphenyl)-1,2,3,5-(1H)-tetrazole. The NMR spectrum was consistent with the proposed structure.
Step F Synthesis of 1-(2-fluoroethyl)-4-(4-methylphenyl)-1,2,3,5-(1H)-tetrazole as an intermediate
Under a nitrogen atmosphere, a stirred solution of 5.0 grams (0.031 mole) 4-(4-methylphenyl)-1,2,3,5-(1H)-tetrazole and 4.8 grams (0.035 mole) of potassium carbonate in 150 mL of acetonitrile was heated to reflux and then cooled to ambient temperature. To this was slowly added 10.0 grams (0.078 mole) of 1-bromo-2-fluoroethane. Upon completion of the addition the reaction mixture was placed in a water bath and cooled to 0° C., where it stirred for one hour. After this time the reaction mixture was heated to reflux, where it stirred for three hours, and then cooled to 0° C., where it stirred for about 18 hours. At the conclusion of this period the reaction mixture was poured into 50 mL of water. The resulting solution was extracted with three 50 mL portions of ethyl acetate. The combined extracts were concentrated under reduced pressure to a residue, which was subjected to column chromatography on silica gel. Elution was accomplished with methylene chloride and acetone. The product-containing fractions were combined and concentrated under reduced pressure, yielding 2.8 grams 1-(2-fluoroethyl)-(4-methylphenyl)-1,2,3,5-(1H)-tetrazole. The NMR spectrum was consistent with the proposed structure.
Step G Synthesis of 4-[1-(2-fluoroethyl)-1,2,3,5-(1H)-tetrazol-4-yl]benzyl bromide as an intermediate
Under a light source a stirred solution of 2.8 grams (0.013 mole) of 1-(2-fluoroethyl)-4-(4-methylphenyl)-1,2,3,5-(1H)-tetrazole, 2.4 grams (0.013 mole) of N-bromosuccinimide, and 0.19 gram (0.0008 mole) of benzoyl peroxide in 100 mL of carbon tetrachloride was heated to reflux. Once at reflux the reaction mixture was stirred for five hours. After this time the heat source was removed and the reaction mixture was stirred for about 18 hours. At the conclusion of this period the reaction mixture was filtered, and the filtrate was concentrated under reduced pressure, yielding 0.59 gram of 4-[1-(2-fluoroethyl)-1,2,3,5-(1H)-tetrazol-4-yl]benzyl bromide. The NMR spectrum was consistent with the proposed structure.
Step H Synthesis of N-{4-[1-(2-fluoroethyl)-1,2,3,5-(1H)-tetrazol-4-yl]phenylmethyl}-N′-[bis(4-trifluoromethylphenyl)methyl]piperazine (Compound 150)
This compound was prepared in the manner of Example 6, with 0.81 gram (0.002 mole) of N-[bis(4-trifluoromethylphenyl)methyl]piperazine, 0.59 gram (0.002 mole) of 4-[1-(2-fluoroethyl)-1,2,3,5-(1H)-tetrazol-4-yl]benzyl bromide, 0.81 gram (0.006 mole) of N,N-diisopropylethylamine as reagents, and 25 mL of dimethyl sulfoxide as solvent. The yield of N-{4-[1-(2-fluoroethyl)-1,2,3,5-(1H)-tetrazol-4-yl]phenylmethyl}-N′-[bis(4-trifluoromethylphenyl)methyl]piperazine was 0.61 gram. The NMR spectrum was consistent with the proposed structure.
EXAMPLE 8 Synthesis of N-[4-(Pyrid-2-yloxy)Phenylmethyl]-N′-[bis(4-Trifluoromethylphenyl)Methyl]Piperazine (Compound 151)
Step A Synthesis of 4-(pyrid-2-yloxy)benzaldehyde as an intermediate
A stirred mixture of 36.7 grams (0.30 mole) of 4-hydroxybenzaldehyde, 12.9 mL (0.15 mole) of 2-fluoropyridine, and 41.0 grams (0.30 mole) of potassium carbonate, and 1.05 grams of 1,4,7,10,13,16-hexaoxacyclooctadecane in 200 mL of dimethyl sulfoxide was heated at 120° C. for four days. The reaction mixture was cooled to ambient temperature, and 500 mL of water was added. The organic and aqueous layers were separated. The aqueous layer was basified with aqueous 10% sodium hydroxide and extracted with two 400 mL portions of diethyl ether. The ether extracts were combined and washed with one 100 mL portion of aqueous 5% sodium hydroxide, followed by one 100 mL portion of aqueous 10% lithium chloride. The organic layer and extracts were combined, dried with sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to yield a residue, which was subjected to column chromatography on silica gel. Elution was accomplished with 15-20% acetone in petroleum ether mixtures. The product-containing fractions were combined and concentrated under reduced pressure, yielding 13.5 grams of 4-(pyrid-2-yloxy)benzaldehyde. The NMR spectrum was consistent with the proposed structure.
Step B Synthesis of 4-(pyrid-2-yloxy)benzyl alcohol as an intermediate
This compound was prepared in the manner of Step A, Example 1, with 1.87 grams ( 0.052 mole) of sodium borohydride, 13.5 grams (0.068 moles) of 4-(pyrid-2-yloxy)benzaldehyde as reagents, and 200mL of ethanol as solvent. The yield of 4-(pyrid-2-yloxy)benzyl alcohol was 13.0 grams. The NMR spectrum was consistent with the proposed structure.
Step C Synthesis of 4-(pyrid-2-yloxy)benzyl chloride as an intermediate
This compound was prepared in the manner of Step B, Example 1, with 1.0 mL (0.012 mole) of pyrdine, 4.4 mL (0.06 mole) of thionyl chloride, 8.0 grams (0.04 mole) of 4-(pyrid-2-yloxy)benzyl alcohol as reagents, and 100 mL of anhydrous methylene chloride. The yield of 4-(pyrid-2-yloxy)benzyl chloride was 0.66 grams. The NMR spectrum was consistent with the proposed structure.
Step D Synthesis of N-[4-(pyrid-2-yloxy)phenylmethyl]-N′-[bis(4-trifluoromethylphenyl)methyl]piperazine (Compound 151)
This compound was prepared in the manner of Example 3, with 1.15 grams (0.003 mole) of N-[bis(4-trifluoromethylphenyl)methyl]piperazine, 0.66 gram (0.003 mole) of 4-(pyrid-2-yloxy)benzyl chloride, 1.3 grams (0.01 mole) of N,N-diisopropylethylamine in 10 mL of dimethyl sulfoxide as reagents and 0.1 gram (0.0005 mole) of sodium iodide as catalyst.. The yield of N-[4-(pyrid-2-yloxy)phenylmethyl]-N′-[bis(4-trifluoromethylphenyl)methyl]-piperazine was 0.75 gram. The NMR spectrum was consistent with the proposed structure.
Representative compounds prepared by the methods exemplified above are listed in Table 1. Characterizing properties are given in Table 2.
Biological Data
The N-heterocyclylalkyl- or N-[(polycyclyl)alkyl]-N′-substituted piperazine derivatives of the present invention were incorporated into an artificial diet for evaluation of insecticidal activity against the tobacco budworm (Heliothis virescens[Fabricius]) in the following manner. Stock solutions of the test chemical in dimethyl sulfoxide were prepared for each rate of application. One hundred microliters of each of the stock solutions was manually stirred into 50 mL of a molten (65-70° C.) wheat germ-based artificial diet. The 50 mL of molten diet containing the test chemical was poured evenly into twenty wells in the outer four rows of a twenty-five well, five row plastic tray. Each well in the tray was about 1 cm in depth, with an opening of 3 cm by 4 cm at the lip. Molten diet containing only dimethylsulfoxide at the levels used in the test chemical-treated diet was poured into the five wells in the third row of the tray. Each tray therefore contained one test chemical at a single rate of application, together with an untreated control. The rates of application, expressed as the negative log of the molar concentration, and the corresponding concentrations of the stock solution prepared for each rate are shown below:
Stock Solution Rate of Application
50 micromolar 4
5 5
0.5 6
0.05 7
0.005 8
Single second instar tobacco budworm larvae were placed in each well. The larvae were selected at a stage of growth at which they uniformly weigh about 5 mg each. Upon completion of infestation, a sheet of clear plastic was heat-sealed over the top of the tray using a common household flat iron. The trays were held at 25° C. at 60% relative humidity for five days in a growth chamber. Lighting was set at 14 hours of light and 10 hours of darkness. After the 5-day exposure period, mortality counts were taken, and the surviving insects were weighed. From the weights of the surviving insects that fed on the treated diet as compared to those insects that fed on the untreated diet, the percent growth inhibition caused by each test chemical was determined.
The compounds of the present invention caused significant inhibition of the growth of the tobacco budworm. The most efficacious compounds were 38, 146, 147, 148, 150, and 151. The data from the diet test are given in Table 3.
Certain N-heterocyclylalkyl- or N-[(polycyclyl)alkyl]-N′-substituted piperazines derivatives causing high growth inhibition in the diet test were also tested for insecticidal activity in foliar evaluations against the tobacco budworm.
In these tests against the tobacco budworm, nine-day-old chick pea plants (Cicer arietinum) were sprayed at 20 psi to runoff on both upper and lower leaf surfaces with solutions of test chemical to provide application rates as high as 1000 ppm of test chemical. The solvent used to prepare the solutions of test chemical was 10% acetone or methanol (v/v) and 0.1% of the surfactant octylphenoxypolyethoxyethanol in distilled water. Four replicates, each containing four chick pea plants, for each rate of application of test chemical were sprayed. The treated plants were transferred to a hood, where they were kept until the spray had dried.
The four chick pea plants in each replicate, treated with test chemical as described above, were removed from their pots by cutting the stems just above the soil line. The excised leaves and stems from the four plants in each replicate were placed in individual 8-ounce paper cups, which contained a moistened filter paper. Five second-instar (4-5 days old) tobacco budworms were counted into each cup, taking care not to cause injury. An opaque plastic lid was placed on each cup, which was then held in a growth chamber for a 96 hour exposure period at 25° C. and 50% relative humidity. At the end of the 96 hour exposure period the cups were opened, and the numbers of dead and live insects were counted. Moribund larvae, which were disoriented or unable to crawl normally, were counted as dead. Based on the insect counts the efficacy of the test chemical was expressed in percent control. Percent control is derived from the total number of dead insects (TD) plus the total number of moribund insects (TM) as compared to the total number of insects (TI) in the test: % Control = TD + TM TI × 100
Figure USH0002007-20011204-M00001
The condition of the test plants was also observed for phytotoxicity and for reduction of feeding damage as compared to an untreated control.
Of the compounds evaluated in the test on foliage, the most active ones were compounds 147, 150, and 151. Compounds 150 and 151 both provided excellent kills at a low concentration. The data from the foliar tests on the tobacco budworm are given in Table 4. The compounds of the invention were also effective against the cabbage looper and the beet armyworm.
For insecticidal application, the active compounds of the invention are formulated into insecticidal compositions by admixture in insecticidally effective amount with adjuvants and carriers normally employed in the art for facilitating the dispersion of active ingredients for the particular utility desired, recognizing the fact that the formulation and mode of application of a toxicant may affect the activity of the material in a given application. Thus, for agricultural use the present insecticidal compounds may be formulated as granules of relatively large particle size, as water-soluble or water-dispersible granules, as powdery dusts, as wettable powders, as emulsifiable concentrates, as solutions, or as any of several other known types of formulations, depending on the desired mode of application.
These insecticidal compositions may be applied either as water-diluted sprays, or dusts, or granules to the areas in which insect control is desired. These formulations may contain as little as 0.1%, 0.2% or 0.5% to as much as 95% or more by weight of active ingredient.
Dusts are free flowing admixtures of the active ingredients with finely divided solids such as talc, natural clays, kieselguhr, flours such as walnut shell and cottonseed flours, and other organic and inorganic solids which act as dispersants and carriers for the toxicant; these finely divided solids have an average particle size of less than about 50 microns. A typical dust formulation useful herein is one containing 1.0 part or less of the insecticidal compound and 99.0 parts of talc.
Wettable powders are in the form of finely divided particles which disperse readily in water or other dispersant. The wettable powder is ultimately applied to the locus where insect control is desired either as a dry dust or as an emulsion in water or other liquid. Typical carriers for wettable powders include Fuller's earth, kaolin clays, silicas, and other highly absorbent, readily wet, inorganic diluents. Wettable powders normally are prepared to contain about 5-80% of active ingredient, depending on the absorbency of the carrier, and usually also contain a small amount of a wetting, dispersing, or emulsifying agent to facilitate dispersion. For example, a useful wettable powder formulation contains 80.8 parts of the insecticidal compound, 17.9 parts of Palmetto clay, and 1.0 part of sodium lignosulfonate and 0.3 part of sulfonated aliphatic polyester as wetting agents.
Other useful formulations for insecticidal applications are emulsifiable concentrates (ECs) which are homogeneous liquid compositions dispersible in water or other dispersant, and may consist entirely of the insecticidal compound and a liquid or solid emulsifying agent, or may also contain a liquid carrier, such as xylene, heavy aromatic naphthas, isophorone, or other non-volatile organic solvent. For insecticidal application these concentrates are dispersed in water or other liquid carrier, and normally applied as a spray to the area to be treated. The percentage by weight of the essential active ingredient may vary according to the manner in which the composition is to be applied, but in general comprises 0.5 to 95% of active ingredient by weight of the insecticidal composition.
Flowable formulations are similar to ECs except that the active ingredient is suspended in a liquid carrier, generally water. Flowables, like ECs, may include a small amount of a surfactant, and contain active ingredient in the range of 0.5 to 95%, frequently from 10 to 50%, by weight of the composition. For application, flowables may be diluted in water or other liquid vehicle, and are normally applied as a spray to the area to be treated.
Typical wetting, dispersing, or emulsifying agents used in agricultural formulations include, but are not limited to, the alkyl and alkylaryl sulfonates and sulfates and their sodium salts; alkylaryl polyether alcohols; sulfated higher alcohols; polyethylene oxides; sulfonated animal and vegetable oils; sulfonated petroleum oils; fatty acid esters of polyhydric alcohols and the ethylene oxide addition products of such esters; and the addition product of long-chain mercaptans and ethylene oxide. Many other types of useful surface-active agents are available in commerce. The surface-active agents, when used, normally comprise from 1 to 15% by weight of the composition.
Other useful formulations include suspensions of the active ingredient in a relatively non-volatile solvent such as water, corn oil, kerosene, propylene glycol, or other suitable solvents.
Still other useful formulations for insecticidal applications include simple solutions of the active ingredient in a solvent in which it is completely soluble at the desired concentration, such as acetone, alkylated naphthalenes, xylene, or other organic solvents. Granular formulations, wherein the toxicant is carried on relatively coarse particles, are of particular utility for aerial distribution or for penetration of cover crop canopy. Pressurized sprays, typically aerosols wherein the active ingredient is dispersed in finely divided form as a result of vaporization of a low boiling dispersant solvent carrier, such as carbon dioxide, propane, or butane, may also be used. Water-soluble or water-dispersible granules are also useful formulations for insecticidal application of the present compounds. Such granular formulations are free-flowing, non-dusty, and readily water-soluble or water-miscible. The soluble or dispersible granular formulations described in U.S. Pat. No. 3,920,442 are useful herein with the present insecticidal compounds. In use by the farmer on the field, the granular formulations, emulsifiable concentrates, flowable concentrates, solutions, etc., may be diluted with water to give a concentration of active ingredient in the range of say 0.1% or 0.2% to 1.5% or 2%.
The active insecticidal compounds of this invention may be formulated and/or applied with other insecticides, fungicides, nematicides, plant growth regulators, fertilizers, or other agricultural chemicals. In using an active compound of this invention, whether formulated alone or with other agricultural chemicals, to control insects, an effective amount and concentration of the active compound is applied to the locus where control is desired. The locus may be, e.g., the insects themselves, plants upon which the insects feed, or the insect habitat. When the locus is the soil, e.g., soil in which agricultural crops have been or will be planted, the composition of the active compound may be applied to and optionally incorporated into the soil. For most applications the effective amount may be as low as, e.g. about 10 to 500 g/ha, preferably about 100 to 250 g/ha.
It is apparent that various modifications may be made in the formulation and application of the compounds of this invention without departing from the inventive concepts herein as defined inventive concepts herein as defined in the claims.
TABLE 1
Insecticidal N-Heterocyclylalkyl- or N-[(Polycyclyl)alkyl]-N′-Substituted-Piperazines
Figure USH0002007-20011204-C00014
Figure USH0002007-20011204-C00015
Figure USH0002007-20011204-C00016
Figure USH0002007-20011204-C00017
Formula I
U is CH2, J is H, m and n are 2, Ph is phenyl
Cpd. R R1 R3 R4 D E G
 1 2-Cl-Ph 3-R2 5-Cl H H
 2 4-Cl-Ph 3-R2 5-Cl H H
 3 3-Cl-Ph 3-R2 5-Cl H H
 4 FIII 3-R2 4-Cl-Ph Ph H H H
 5 FIII 3-R2 4-Cl-Ph Ph 4-Cl H H
 6 FIII 3-R2 4-Cl-Ph Ph 5-Cl H H
 7 FIII 3-R2 4-Cl-Ph Ph 6-Cl H H
 8 FIII 3-R2 4-Cl-Ph Ph 7-Cl H H
 9 FIII 3-R2 4-Cl-Ph Ph 5-OH H H
 10 FIII 3-R2 4-Cl-Ph Ph 5-OCH3 H H
 11 FIII 3-R2 4-Cl-Ph Ph 5-CN H H
 12 FIII 3-R2 4-Cl-Ph Ph 5-OCH3 6-OCH3 H
 13* FIII 3-R2 4-Cl-Ph Ph 4-Cl H H
*J is CH3
Formula I
R is FIII, R1 is 3-R2, U is CH2, J is H, m and n are 2, Ph is phenyl
Cpd. R3 R4 D E G
14 4-Cl-Ph Ph —O(CH2)O— H
15 4-Cl-Ph 4-Cl-Ph H H H
16 4-Cl-Ph 4-Cl-Ph 2-CH3 H H
17 4-Cl-Ph 4-Cl-Ph 4-Cl H H
18 4-Cl-Ph 3-Cl-Ph 4-Cl H H
19 4-Cl-Ph 2-Cl-Ph 4-Cl H H
20 4-Cl-Ph 4-Cl-Ph 4-OH H H
21 4-Cl-Ph 4-Cl-Ph 4-CH3 H H
22 4-Cl-Ph 4-Cl-Ph 4-NO2 H H
23 4-Cl-Ph 4-Cl-Ph 4-CN H H
24 4-Cl-Ph 4-Cl-Ph 4-CH(CH3)2 H H
25 4-Cl-Ph 4-Cl-Ph 4-CF3 H H
26 4-Cl-Ph 4-Cl-Ph 4-F H H
27 4-Cl-Ph 4-Cl-Ph 5-F H H
28 4-Cl-Ph 4-Cl-Ph 4-OCH3 H H
29 4-Cl-Ph 4-Cl-Ph 5-OCH3 H H
30 4-Cl-Ph 4-Cl-Ph 4-O(CH2)3CH3 H H
31 4-Cl-Ph 4-Cl-Ph 4-OS(O2)CF3 H H
32 4-Cl-Ph 4-Cl-Ph 4-OC(O)CH3 H H
33 4-Cl-Ph 4-Cl-Ph 4-NHC(O)C6H5 H H
34 4-Cl-Ph 4-OCH3-Ph 4-Cl H H
35 4-F-Ph 4-F-Ph 4-F H H
36 4-F-Ph 4-F-Ph 2-CH3 H H
37 4-CH3-Ph 4-CH3-Ph 4-F H H
38 4-OCF3-Ph 4-OCF3-Ph 4-F H H
39 4-Cl-Ph 2,4-Cl2-Ph 4-Cl H H
40 4-Cl-Ph 2,4-Cl2-Ph 4-F H H
41 4-Cl-Ph 3,4-Cl2-Ph 4-Cl H H
42 4-Cl-Ph 3,5-Cl2-Ph 4-Cl H H
43 4-Cl-Ph 4-Cl-Ph 4-Cl 5-Cl H
Formula I
R is FIII, R1 is 3-R2, U is CH2, J is H, m and n are 2, Ph is phenyl
Cpd. R3 R4 D E G
44 4-Cl-Ph 4-Cl-Ph 4-F 5-Cl H
45 4-Cl-Ph 4-Cl-Ph 4-F 5-CH3 H
46 4-Cl-Ph 4-Cl-Ph 4-CH3 5-F H
47 4-Cl-Ph 4-Cl-Ph 4-F 6-F H
48 4-Cl-Ph 4-Cl-Ph 4-F 6-F 5-OCH3
49 4-Cl-Ph 4-Cl-Ph 4-OCH3 5-OCH3 H
50 4-Cl-Ph 4-Cl-Ph 4-C(O)CH3 H H
51 4-Cl-Ph 4-Cl-Ph 4-C(O)OCH(CH3)2 H H
Formula II
R is FIII, R1 is 3-R2, U is CHZ, E, G, and J are H, is H, Ph is phenyl
Cpd. R3 R4 D Z A B
52 4-Cl-Ph Ph H —CH3 H H
53 4-Cl-Ph Ph 4-OCH3 —CH3 H H
54 4-Cl-Ph Ph H —C2H5 H H
55 4-Cl-Ph Ph 5-OCH3 —(CH2)2CH3 H H
56 4-Cl-Ph 4-Cl-Ph 4-Cl —CH3 H H
57 4-Cl-Ph 4-Cl-Ph 4-Cl —(CH2)5CH3 H H
58 4-Cl-Ph 4-Cl-Ph 4-Cl
Figure USH0002007-20011204-C00018
H H
59 4-Cl-Ph 4-Cl-Ph 4-Cl Ph H H
60 4-Cl-Ph 4-Cl-Ph 4-Cl H 2-CH3 5-CH3
Formula I
R is FIII, R1 is 3-R2, U is CH2, J is H, Ph is phenyl
Cpd. R3 R4 D E G m n
61 4-Cl-Ph 4-Cl-Ph 4-Cl H H 2 1
62 4-Cl-Ph 4-Cl-Ph 4-Cl H H 3 1
63 4-Cl-Ph 4-Cl-Ph 4-Cl H H 2 3
Formula I
U is CH2, J is H, m and n are 2, Ph is phenyl
Cpd. R R1 R3 R4 D E G
64 FIII 2-R2 4-Cl-Ph 4-Cl-Ph H H H
65 FIII 2-R2 4-Cl-Ph 4-Cl-Ph 5-F H H
Formula I
R1 is 3-R2, U is (CH2)2, D, E, G and J are H, m and n are 2
Cpd. R Cpd. R
66
Figure USH0002007-20011204-C00019
68
Figure USH0002007-20011204-C00020
67
Figure USH0002007-20011204-C00021
69
Figure USH0002007-20011204-C00022
Formula I
U is (CH2)2, J is H, m and n are 2, Ph is phenyl
Cpd. R R1 R3 R4 D E G
70 FIII 3-R2 Ph Ph H H H
71 FIII 3-R2 Ph 4-Cl-Ph H H H
72 FIII 3-R2 4-Cl-Ph 4-Cl-Ph H H H
73 FIII 3-R2 4-F-Ph 4-F-Ph H H H
74 FIII 3-R2 Ph Ph 5-F H H
75 FIII 3-R2* Ph 4-Cl-Ph 5-F H H
76 FIII 3-R2 4-Cl-Ph Ph 5-OCH3 H H
*3-R2 has a 1-CH3 sustituent
Formula I
U is (CH2)p, m and n are 2, Ph is phenyl
Cpd. R R1 R3 R4 p
77 FIII
Figure USH0002007-20011204-C00023
Ph 4-Cl-Ph 1
78 FIII
Figure USH0002007-20011204-C00024
4-Cl-Ph 4-Cl-Ph 1
79 FIII
Figure USH0002007-20011204-C00025
Ph 4-Cl-Ph 1
80 FIII
Figure USH0002007-20011204-C00026
4-Cl-Ph 4-Cl-Ph 1
81 FIII
Figure USH0002007-20011204-C00027
4-F-Ph 4-F-Ph 1
82 FIII
Figure USH0002007-20011204-C00028
4-Cl-Ph Ph 3
Formula I
U is C═O, J is H, m and n are 2, Ph is phenyl
Cpd. R R1 R3 R4 D E G
83 FIII 3-R2 Ph 4-Cl-Ph H H H
84 FIII 3-R2 4-Cl-Ph 4-Cl-Ph H H H
85 FIII 2-R2 4-Cl-Ph 4-Cl-Ph H H H
86 FIII 2-R2 4-Cl-Ph 4-Cl-Ph 5-F H H
Formula I
U is (C═O)p, m and n are 2, Ph is phenyl
Cpd. R R1 R3 R4 p
87 FIII
Figure USH0002007-20011204-C00029
Ph H 1
88 FIII
Figure USH0002007-20011204-C00030
H Ph 1
89(HCl) FIII
Figure USH0002007-20011204-C00031
H Ph 1
90 FIII
Figure USH0002007-20011204-C00032
4-F-Ph 4-F-Ph 1
91 FIII
Figure USH0002007-20011204-C00033
4-Cl-Ph Ph 2
Formula I
U is (CH2)p, D, E, G, and J are H, m and n are 2, Ph is phenyl
Cpd. R R1 R3 R4 p
92 FIII 3-R2 Ph Ph 1
93 FIII 3-R2 4-F-Ph Ph 1
94 FIII 3-R2 4-F-Ph 4-F-Ph 1
95 FIII 3-R2 4-CH3-Ph 4-CH3-Ph 3
96 FIII 3-R2 4-Cl-Ph 4-Cl-Ph 3
97 FIII 3-R2 4-F-Ph 4-F-Ph 3
98(HCl) FIII 3-R2 Ph Ph 4
Formula I
U is (CH2)2, m and n are 2, Ph is phenyl
Cpd. R R1 R3 R4
 99 FIII
Figure USH0002007-20011204-C00034
4-OCF3-Ph 4-OCF3-Ph
100 FIII
Figure USH0002007-20011204-C00035
4-OCF3-Ph 4-OCF3-Ph
Formula I
U is —CH2—CH═CH—, m and n are 2, Ph is phenyl
Cpd. R R1 R3 R4
101 FIII Ph Ph Ph
102(HCl) FIII Ph 4-F-Ph 4-F-Ph
103 FIII 4-OCH3-Ph 4-F-Ph 4-F-Ph
104 FIII 4-F-Ph 4-F-Ph 4-F-Ph
105 FIII 4-Cl-Ph 4-F-Ph 4-F-Ph
106 FIII
Figure USH0002007-20011204-C00036
4-F-Ph 4-F-Ph
107 FIII
Figure USH0002007-20011204-C00037
4-F-Ph 4-F-Ph
108 FIII
Figure USH0002007-20011204-C00038
4-F-Ph 4-F-Ph
Formula I
U is —CH2—CH═CH—, m and n are 2, Ph is phenyl
Cpd. R R1 R3 R4
109 FIII
Figure USH0002007-20011204-C00039
4-F-Ph 4-F-Ph
110 FIII
Figure USH0002007-20011204-C00040
Ph Ph
111 FIII
Figure USH0002007-20011204-C00041
4-F-Ph 4-F-Ph
Formula I
U is CH2, m and n are 2, Ph is phenyl
Cpd. R R1 R3 R4
112 FIII
Figure USH0002007-20011204-C00042
4-F-Ph 4-F-Ph
113 FIII
Figure USH0002007-20011204-C00043
4-F-Ph 4-F-Ph
114 FIII
Figure USH0002007-20011204-C00044
Ph Ph
Formula I
U is —CH2—CH═CH—, m and n are 2, Ph is phenyl
Cpd. R R1 R3 R4
115 FIII
Figure USH0002007-20011204-C00045
4-Cl-Ph 4-Cl-Ph
116 FIII
Figure USH0002007-20011204-C00046
4-OCF3-Ph 4-OCF3-Ph
117 FIII
Figure USH0002007-20011204-C00047
4-CH3-Ph 4-CH3-Ph
118 FIII
Figure USH0002007-20011204-C00048
4-CN-Ph 4-CN-Ph
119 FIII
Figure USH0002007-20011204-C00049
4-OCH3-Ph 4-OCH3-Ph
Formula I
U is C═O, m and n are 2, Ph is phenyl
Cpd. R R1 R3 R4
120 FIII
Figure USH0002007-20011204-C00050
4-Cl-Ph 4-Cl-Ph
121 FIII
Figure USH0002007-20011204-C00051
4-Cl-Ph 4-Cl-Ph
122 FIII
Figure USH0002007-20011204-C00052
Ph 4-Cl-Ph
Formula I
U is CH2, m and n are 2, Ph is phenyl
Cpd. R R1 R3 R4
123 FIII
Figure USH0002007-20011204-C00053
4-Cl-Ph 4-Cl-Ph
124 FIII
Figure USH0002007-20011204-C00054
4-Cl-Ph 4-Cl-Ph
Formula II
U is CH2, A and B are H, Ph is phenyl
Cpd. R R1 R3 R4
125 FIII
Figure USH0002007-20011204-C00055
Ph Ph
126 FIII 3-C(CH3)3-Ph Ph 4-Cl-Ph
127 FIII
Figure USH0002007-20011204-C00056
2-Cl-Ph 2-Cl-Ph
128 FIII Ph 4-F-Ph 4-F-Ph
129 FIII
Figure USH0002007-20011204-C00057
4-F-Ph 4-F-Ph
130 FIII
Figure USH0002007-20011204-C00058
4-F-Ph 4-F-Ph
131 FIII
Figure USH0002007-20011204-C00059
4-F-Ph 4-F-Ph
132 FIII
Figure USH0002007-20011204-C00060
4-F-Ph 4-F-Ph
133 FIII
Figure USH0002007-20011204-C00061
4-F-Ph 4-F-Ph
134 FIII
Figure USH0002007-20011204-C00062
4-F-Ph 4-F-Ph
135 FIII
Figure USH0002007-20011204-C00063
4-F-Ph 4-F-Ph
136 FIII
Figure USH0002007-20011204-C00064
4-F-Ph 4-F-Ph
137 FIII
Figure USH0002007-20011204-C00065
4-F-Ph 4-F-Ph
138 FIII
Figure USH0002007-20011204-C00066
4-F-Ph 4-F-Ph
139 FIII
Figure USH0002007-20011204-C00067
4-CF3-Ph 4-CF3-Ph
140 FIII
Figure USH0002007-20011204-C00068
4-CF3-Ph 4-CF3-Ph
141 FIII
Figure USH0002007-20011204-C00069
4-CF3-Ph 4-CF3-Ph
142 FIII
Figure USH0002007-20011204-C00070
4-CF3-Ph 4-CF3-Ph
143 FIII
Figure USH0002007-20011204-C00071
4-CF3-Ph 4-CF3-Ph
144 FIII
Figure USH0002007-20011204-C00072
4-CF3-Ph 4-CF3-Ph
145 FIII
Figure USH0002007-20011204-C00073
4-CF3-Ph 4-CF3-Ph
146 FIII
Figure USH0002007-20011204-C00074
4-CF3-Ph 4-CF3-Ph
147 FIII
Figure USH0002007-20011204-C00075
4-CF3-Ph 4-CF3-Ph
148 FIII
Figure USH0002007-20011204-C00076
4-CF3-Ph 4-CF3-Ph
149 FIII
Figure USH0002007-20011204-C00077
4-CF3-Ph 4-CF3-Ph
150 FIII
Figure USH0002007-20011204-C00078
4-CF3-Ph 4-CF3-Ph
151 FIII
Figure USH0002007-20011204-C00079
4-CF3-Ph 4-CF3-Ph
152 FIII 4-OCH3-Ph 4-OCH3-Ph 4-OCH3-Ph
153 FIII 4-OCH3-Ph Ph Ph
(diHCl)
154 FIII Ph Ph 4-Cl-Ph
(diHCl)
155 FIII 3-CH3-Ph Ph 4-Cl-Ph
(diHCl)
156 FIII 4-C(CH3)3-Ph Ph 4-Cl-Ph
(diHCl)
157 (diHCl) FIII
Figure USH0002007-20011204-C00080
Ph 4-Cl-Ph
158 FIII
Figure USH0002007-20011204-C00081
4-OCF3-Ph 4-OCF3-Ph
159 FIII
Figure USH0002007-20011204-C00082
4-OCF3-Ph 4-OCF3-Ph
160 FIII
Figure USH0002007-20011204-C00083
4-OCF3-Ph 4-OCF3-Ph
161 FIII
Figure USH0002007-20011204-C00084
4-OCF3-Ph 4-OCF3-Ph
161 FIII
Figure USH0002007-20011204-C00085
4-OCF3-Ph 4-OCF3-Ph
162 FIII
Figure USH0002007-20011204-C00086
4-OCF3-Ph 4-OCF3-Ph
163 FIII
Figure USH0002007-20011204-C00087
4-OCF3-Ph 4-OCF3-Ph
164 FIII
Figure USH0002007-20011204-C00088
4-OCF3-Ph 4-OCF3-Ph
165 FIII
Figure USH0002007-20011204-C00089
4-OCF3-Ph 4-OCF3-Ph
166 FIII
Figure USH0002007-20011204-C00090
4-OCF3-Ph 4-OCF3-Ph
167 FIII
Figure USH0002007-20011204-C00091
4-OCF3-Ph 4-OCF3-Ph
168 FIII
Figure USH0002007-20011204-C00092
4-OCF3-Ph 4-OCF3-Ph
169 FIII
Figure USH0002007-20011204-C00093
4-OCF3-Ph 4-OCF3-Ph
170 FIII
Figure USH0002007-20011204-C00094
4-OCF3-Ph 4-OCF3-Ph
171 FIII
Figure USH0002007-20011204-C00095
4-OCF3-Ph 4-OCF3-Ph
172 FIII
Figure USH0002007-20011204-C00096
4-OCF3-Ph 4-OCF3-Ph
173 FIII
Figure USH0002007-20011204-C00097
4-CF3-Ph 4-CF3-Ph
174 FIII
Figure USH0002007-20011204-C00098
4-CF3-Ph 4-CF3-Ph
175 FIII
Figure USH0002007-20011204-C00099
4-CF3-Ph 4-CF3-Ph
176 FIII
Figure USH0002007-20011204-C00100
4-CF3-Ph 4-CF3-Ph
177 FIII
Figure USH0002007-20011204-C00101
4-CF3-Ph 4-CF3-Ph
178 FIII
Figure USH0002007-20011204-C00102
4-CF3-Ph 4-CF3-Ph
179 FIII
Figure USH0002007-20011204-C00103
4-CF3-Ph 4-CF3-Ph
180 FIII
Figure USH0002007-20011204-C00104
4-CF3-Ph 4-CF3-Ph
181 FIII
Figure USH0002007-20011204-C00105
4-CF3-Ph 4-CF3-Ph
182 FIII
Figure USH0002007-20011204-C00106
4-CF3-Ph 4-CF3-Ph
183 FIII
Figure USH0002007-20011204-C00107
4-CF3-Ph 4-CF3-Ph
Formula II
U is C═O, A and B are H, Ph is phenyl
Cpd. R R1 R3 R4
184 FIII Ph Ph Ph
Formula II
R is FIII, U is CH2, Ph is phenyl
Cpd. R1 R3 R4 A B
185 4-OCH3-Ph 4-OCF3-Ph 4-OCF3-Ph 1-(═O) 4-(═O)
(Isomer 1)
186 4-OCH3-Ph 4-OCF3-Ph 4-OCF3-Ph 1-(═O) 4-(═O)
(Isomer 2)
TABLE 2
Melting Point (° C.) Melting Point (° C.)
Cmpd No Physical State Cmpd No Physical State
 1 62.74 dec 59 100-105
 2 72 60  96-118
 3 58, dec @ 68 61 104-109
 4 pale oil 62 112-116
 5  96-105 63 75-78
 6 78-86 64 foam
 7 75-85 65 foam
 8 75-90 66 viscous oil
 9 115-135 67 soft solid
10 72-76 68 82 dec
11 oil 69 oil
12 108 dec 70 62-72
13 viscous oil 71 65-76
14 oil 72 100-110 dec
15 95, 99 dec 73 67-76
16 106-110 74 146 dec
17 oil 75 155-180 dec
18 oil 76 118 dec
19 oil 77 colorless oil
20 yellow glassy solid 78 84-87
21 thick oil 79 pale oil
22 115 dec 81 164-166
23 121 dec 82 137 dec
24 108-113 83 111 shrinks
25 white glassy solid 78 84-87
26 oil 85 118-121
27 98, 106 dec 86 183-185
28 oil 87 oil
29 oil 88 70-79
30 oil 89 150-165
31 oil 90 193-195
32 105-120 91 134 shrinks
33 125-135 92 solid
34  92-100 93 solid
35 oil 94 solid
36 65-73 95 solid
37 oil 96 solid
38 oil 97 solid
39 oil 98 solid
49  90-108 99 oil
50 108-115 100  92-94
51 94-97 101  solid
52 oil 102  218-222
53 oil 103  83-87
54 tan powder mp 104  liquid
shrinks at 94 c
55 80-86 105  liquid
56 82-86 106  liquid
57 144-149 107  paste
58 85-90 108  63-66
109  140-141 133  liquid
110  143-145 134  solid
111  93-95 135  oil
112  oil 136  liquid
113  92-94 137  solid
114  110-113 138  liquid paste
115  48-52 139  oil
116  liquid 140  oil
117  solid 141  oil
118  liquid 142  oil
119  78-83 143  oil
120  foam 144  oil
121  foam 145  oil
122  160-161 146  oil
123  foam 147  oil
124  foam 148  159-162
125  108-109 149  oil
127  liquid 150  oil
128  124-127 c 151  liquid
129  liquid 152  oil
130  liquid 154  221.5-222.2
131  liquid 185  152-154
132  oil 186  157-159
TABLE 3
Insecticidal Activity
When Incorporated into the Diet of Tobacco Budworm
Rate of Percent Growth
Cmpd. No. Application1 Inhibition2,3
 1 4 24
 2 4 10
 5 4 90
 6 4 76
 7 4 43
 8 4 44
10 4 80
11 4 54
12 4 28
13 4 60
14 4 46
15 4 94a
16 4 35
17 4 98
18 4 83
19 4 92
20 4 18
21 4 95a
22 4 96
23 4 89a
24 3.5 −5
25 4 82a
26 4 98a
27 4 98a
28 4 96a
29 4 66
30 4 30a
31 4 −1
32 4 10
33 4 15
34 4 97a
35 4 90
37 4 96
38 4 100a
39 4 98a
40 4 99
41 4 90
42 4 7
43 4 95
44 4 95
45 4 92
46 4 96
47 4 97
48 4 90
49 4 82
50 4 85a
51 4 25a
53 4 31
54 4 64
55 4 67
56 4 32
57 3.5 5
58 4 15
59 4 4
60 4 77
61 4 26
62 4 29
63 4 81
64 4 21
65 4 5
67 4 31
72 4 62a
73 4 36
74 4 −6
75 4 2
76 4 38
78 .35 −7
80 4 86
81 4 10
82 4 14
84 3.5 16
85 4 1
86 4 1
90 4 −3
91 4 9
99 3.5 100
100 4 63
101 4 7a
102 4 35b
114 4 26
115 4 54
116 4 100b
117 4 9
118 3.5 13
119 3.5 3
122 4 11
123 4 54a
124 4 9
129 4 38
130 4 78
131 4 89
133 4 48
136 4 87
138 4 9
139 4 33
140 4 94
141 4 100
142 4 90
143 4 77
144 4 43
145 4 99
146 4 100
147 4 100
148 4 98
149 4 100
150 4 100
151 4 100
152 4 98a
182 4 92
186 4 40
TABLE 4
Insecticidal Activity When Applied as Foliar Sprays
Rate of Percent
Application Control1
Cmpd No. (ppm) TBW
4 1000   0
6 300  0
17 300  62a
26 300  60
38 300 100a
39 300  95
147 300 100
150 100  95
151 100  90
152 1000   40
a = average of two tests
1Percent control is derived from the total number of dead insects (TD) plus the total number of moribund insects (TM) as compared to the total number of insects (TI) used in the test,
% Control = TD + TM TI × 100
Figure USH0002007-20011204-M00002

Claims (49)

What is claimed is:
1. A compound of the formula
Figure USH0002007-20011204-C00108
in which:
A and B are independently selected from lower alkyl;
U is selected from lower alkylidene, lower alkenylidene, and CH—Z, where Z is independently selected from hydrogen, lower alkyl, lower cycloalkyl, and phenyl;
R is
Figure USH0002007-20011204-C00109
 where R3 and R4 are independently selected from phenyl, optionally substituted with, halogen, lower alkyl, lower haloalkyl, lower alkoxy, lower haloalkoxy, lower alkenyl, or phenyl;
R1 is phenyl, naphthyl, tetrazolylphenyl, phenylcyclopropyl, phenoxyphenyl, benzyloxyphenyl, pyridylphenyl, pyridyloxyphenyl, or thiadiazolyloxyphenyl, each optionally substituted with halogen, cyano, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy, amino, lower dialkylamino, nitro, lower haloalkylsulfonyloxy, lower alkylcarbonyloxy, lower alkylcarbonylamino, lower alkoxycarbonyl, lower alkoxyalkoxycarbonyl, lower cycloalkylalkoxycarbonyl, lower alkoxyalkylalkoxycarbonyl, lower alkoxycarbonylamino, alkoxythiocarbonylamino, lower alkyldithiocarbonylamino, lower dialkyldioxolylalkoxycarbonylamino, or halophenylamino; or lower alkyl substituted with any one of the foregoing cyclic R1 groups;
m is 2 or 3 and n is 1, 2, or 3;
halogen is chlorine, fluorine, or bromine, lower means having from 1 to 6 carbon atoms, and any aliphatic chain of three or more carbons may be straight or branched.
2. A compound of claim 1 in which
U is selected from lower alkylidene, carbonyl, lower alkenylidene, and CH—Z, where Z is independently selected from hydrogen and lower alkyl;
R is and
Figure USH0002007-20011204-C00110
 where R3 and R4 are independently selected from hydrogen and phenyl, optionally substituted with halogen, lower alkyl, lower haloalkyl, lower alkoxy, lower haloalkoxy;
R1 is phenyl, tetrazolylphenyl, pyridylphenyl, pyridyloxyphenyl; each optionally substituted with halogen, cyano, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy, amino, lower dialkylamino, lower alkylcarbonyloxy, lower alkylcarbonylamino, lower alkoxycarbonyl, lower alkoxyalkoxycarbonyl, lower cycloalkylalkoxycarbonyl, lower alkoxyalkylalkoxycarbonyl, or lower alkoxycarbonylamino; or lower alkyl substituted with any one of the foregoing cyclic R1 groups;
m and n are 2; and
halogen is chlorine or fluorine, for aliphatic groups lower means having from 1 to 3 carbon atoms, and for alicyclic groups lower means having 3 to 6 carbons.
3. A compound of claim 2 of the formula
Figure USH0002007-20011204-C00111
in which
R is
Figure USH0002007-20011204-C00112
 where R3 and R4 are independently selected from phenyl substituted in the 4-position with halogen, lower alkyl, lower haloalkyl, lower alkoxy, or lower haloalkoxy;
R1 is phenyl substituted in the 4-position with lower dialkylamino, lower alkoxycarbonylamino, tetrazolyl, pyridyl, or pyridyloxy; each tetrazolyl or pyridyl group optionally substituted with halogen, cyano, lower alkyl, lower haloalkyl, or lower alkoxy;
m and n are 2; and
halogen is chlorine or fluorine, for aliphatic groups lower means having from 1 to 3 carbon atoms, and for alicyclic groups lower means having 3 to 6 carbons.
4. A compound of claim 3 in which U is CH2, and R3 and R4 are independently selected from chlorophenyl, fluorophenyl, methylphenyl, trifluoromethylphenyl, methoxyphenyl, and trifluoromethoxyphenyl.
5. A composition of claim 3 in which
R is
Figure USH0002007-20011204-C00113
 where R3 and R4 are independently selected from 4-chlorophenyl, 4-fluorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-methoxyphenyl, and 4-trifluoromethoxyphenyl;
R1 is 3-R2, where R2 is
Figure USH0002007-20011204-C00114
 where D is selected from hydrogen, hydroxy, chloro, fluoro; methyl, phenylcarbonylamino, and methoxy, and E and G are independently selected from hydrogen, chloro, fluoro; methyl, and methoxy.
6. A composition of claim 5 in which
R2 is
Figure USH0002007-20011204-C00115
 in which D is selected from hydrogen, 4-chloro, 4-fluoro, 4-hydroxy, and 4-phenylcarbonylamino; E is selected from hydrogen, 5-chloro, 5-methyl, 6-fluoro; G is selected from hydrogen and 5-methoxy; and R3 and R4 are independently selected from 4-chlorophenyl, 4-fluorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, and 4-trifluoromethoxyphenyl.
7. A composition of claim 6 in which R3 and R4 are each 4-trifluoromethoxyphenyl.
8. A composition of claim 6 in which E and G are hydrogen.
9. A composition of claim 8 in which D is 4-fluoro.
10. The composition of claim 9 in which R3 and R4 are each 4-trifluoromethoxyphenyl.
11. The composition of claim 9 in which R3 and R4 are each 4-chlorophenyl.
12. The composition of claim 9 in which R3 and R4 are each 4-fluorophenyl.
13. The composition of claim 9 in which R3 and R4 are each 4-methylphenyl.
14. A composition of claim 6 in which and R3 and R4 are each 4-chlorophenyl.
15. A composition of claim 14 in which D is 4-fluoro.
16. The composition of claim 15 in which E is 5-chloro, and G is hydrogen.
17. The composition of claim 15 in which E is 5-methyl, and G is hydrogen.
18. The composition of claim 15 in which E is 6-fluoro, and G is hydrogen.
19. The composition of claim 15 in which E is 6-fluoro, and G is 5-methoxy.
20. A composition of claim 14 in which E and G are hydrogen.
21. The composition of claim 20 in which D is 4-hydroxy.
22. The composition of claim 20 in which D is 4-phenylcarbonylamino.
23. A compound of claim 4 in which
R is
Figure USH0002007-20011204-C00116
 where R3 and R4 are independently selected from 4-chlorophenyl, 4-fluorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-methoxyphenyl, and 4-trifluoromethoxyphenyl;
R1 is phenyl substituted in the 4-position with lower dialkylamino, lower alkoxycarbonylamino, tetrazolyl, pyridyl, or pyridyloxy; each tetrazolyl or pyridyl group optionally substituted with halogen, cyano, lower alkyl, lower haloalkyl, or lower alkoxy, with the proviso that when R1 is lower dialkylaminophenyl, R3 and R4 are each trifluoromethoxyphenyl.
24. A compound of claim 23 in which R1 is lower dialkylaminophenyl.
25. The compound of claim 24 in which R1 is dimethylaminophenyl.
26. A compound of claim 23 in which
R1 is phenyl substituted in the 4-position with lower alkoxycarbonylamino, tetrazol-4-yl or pyrid-2-yloxy; each tetrazolyl or pyridyl group optionally substituted with lower alkyl, lower haloalkyl, or lower alkoxy; and
R3 and R4 are independently selected from 4-trifluoromethylphenyl and 4-trifluoromethoxyphenyl.
27. A compound of claim 26 in which R3 and R4 are each 4-trifluoromethylphenyl.
28. The compound of claim 27 in which R1 is N-4-(methoxycarbonylamino)phenyl.
29. The compound of claim 27 in which R1 is N-4-(1-methylethoxycarbonylamino)phenyl.
30. The compound of claim 27 in which R1 is N-4-(1-methyl-1,2,3,5-(1-H)-tetrazol4-yl)phenyl.
31. The compound of claim 27 in which R1 is N-4-[1-(2-fluorooethyl)-1,2,3,5-(1-H)-tetrazol-4-yl]phenyl.
32. The compound of claim 27 in which R1 is N-4-(pyrid-2-yloxy)phenyl.
33. The compound N-[bis(4-trifluoromethoxyphenyl)methyl]piperazine.
34. An insecticidal composition comprising an insecticidally effective amount of an adjuvant or carrier and at least one compound of the formula
Figure USH0002007-20011204-C00117
in which:
A and B are independently selected from lower alkyl;
U is selected from lower alkylidine, lower alkenylidene, and CH—Z, where Z is independently selected from hydrogen, lower alkyl, lower cycloalkyl, and phenyl;
R is selected from phenyl, optionally substituted with halogen, lower alkyl, lower alkoxy, phenyl, or phenoxy, and from a dibenzocyclo(C5-8)alkyl, optionally substituted with halogen, lower alkyl, or lower alkoxy; and
Figure USH0002007-20011204-C00118
 where R3 and R4 are independently selected from phenyl, optionally substituted with, halogen, lower alkyl, lower haloalkyl, lower alkoxy, lower haloalkoxy, lower alkenyl, or phenyl;
R1 is phenyl, naphthyl, tetrazolylphenyl, phenylcyclopropyl, phenoxyphenyl, benzyloxyphenyl, pyridylphenyl, pyridyloxyphenyl, thiadiazolyloxyphenyl, benzothienyl, benzimidazolyl, indolyl, pyrrolyl, or quinolyl, each optionally substituted with halogen, cyano, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy, amino, lower dialkylamino, nitro, lower haloalkylsulfonyloxy, lower alkoxycarbonyl, lower alkoxyalkoxycarbonyl, lower cycloalkylalkoxycarbonyl, lower alkoxyalkylalkoxycarbonyl, lower alkoxycarbonylamino, alkoxythiocarbonylamino, lower alkyldithiocarbonylamino, lower dialkyldioxolylalkoxycarbonylamino, or halophenylamino; or lower alkyl substituted with any one of the foregoing cyclic R1 groups; or 3-R2, where R2 is
Figure USH0002007-20011204-C00119
 where D, E, and G are independently selected from hydrogen, hydroxy, halogen, cyano, lower alkyl, lower haloalkyl, lower alkoxy, nitro, lower haloalkylsulfonyloxy, lower alkylcarboxylato, lower alkylcarbonylamino, arylcarbonylamino, lower alkylcarbonyl. lower alkoxycarbonyl, or D and E taken together form the group —O(CH2)O—, and J is hydrogen or lower alkyl;
m is 2or 3 and n is 1, 2, or 3;
halogen is chlorine, fluorine, or bromine, lower means having from 1 to 6 carbon atoms, and any aliphatic chain of three or more carbons may be straight or branched.
35. A composition of claim 34 in which
U is selected from lower alkylidene, carbonyl, lower alkenylidene, and CH—Z, where Z is independently selected from hydrogen and lower alkyl;
R is selected from phenyl, optionally substituted with halogen, lower alkyl, lower alkoxy, phenyl, or phenoxy; and
Figure USH0002007-20011204-C00120
 where R3 and R4 are independently selected from hydrogen and phenyl, optionally substituted with halogen, lower alkyl, lower haloalkyl, lower alkoxy, lower haloalkoxy;
R1 is phenyl, tetrazolylphenyl, pyridylphenyl, pyridyloxyphenyl; each optionally substituted with halogen, cyano, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy, amino, lower dialkylamino, lower alkylcarbonyloxy, lower alkylcarbonylamino, lower alkoxycarbonyl, lower alkoxyalkoxycarbonyl, lower cycloalkylalkoxycarbonyl, lower alkoxyalkylalkoxycarbonyl, or lower alkoxycarbonylamino; or lower alkyl substituted with any one of the foregoing cyclic R1groups; or 3-R2, where R2 is
Figure USH0002007-20011204-C00121
 where D is hydrogen, hydroxy, chloro, fluoro; methyl, methoxy, or phenylcarbonylamino; E and G are independently selected from hydrogen, chloro, fluoro; methyl, and methoxy, with the proviso that when R1 is lower dialkylaminophenyl, R3 and R4 are each trifluoromethoxyphenyl;
m and n are 2; and
halogen is chlorine or fluorine, for aliphatic groups lower means having from 1 to 3 carbon atoms, and for alicyclic groups lower means having 3 to 6 carbons.
36. A composition of claim 35 wherein said compound is of the formula
Figure USH0002007-20011204-C00122
in which
R is
Figure USH0002007-20011204-C00123
 where R3 and R4 are independently selected from phenyl substituted in the 4-position with halogen, lower alkyl, lower haloalkyl, lower alkoxy, or lower haloalkoxy;
R1 is phenyl substituted in the 4-position with lower dialkylamino, lower alkoxycarbonylamino, tetrazolyl, pyridyl, or pyridyloxy; each tetrazolyl or pyridyl group optionally substituted with halogen, cyano, lower alkyl, lower haloalkyl, or lower alkoxy; or 3-R2, where R2 is
Figure USH0002007-20011204-C00124
 where D is hydrogen, 4-chloro, 4-fluoro, 4-hydroxy, or 4-phenylcarbonylamino; E is hydrogen, 5-chloro, 5-methyl, or 6-fluoro; G is hydrogen or 5-methoxy;
m and n are 2; and
halogen is chlorine or fluorine, for aliphatic groups lower means having from 1 to 3 carbon atoms, and for alicyclic groups lower means having 3 to 6 carbons.
37. A composition of claim 36 in which U is CH2, and R3 and R4 are independently selected from chlorophenyl, fluorophenyl, methylphenyl, trifluoromethylphenyl, methoxyphenyl, and trifluoromethoxyphenyl.
38. A composition of claim 37 in which
R is
Figure USH0002007-20011204-C00125
 where R3 and R4 are independently selected from 4-chlorophenyl, 4-fluorophenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-methoxyphenyl, and 4-trifluoromethoxyphenyl;
R1 is phenyl substituted in the 4-position with lower dialkylamino, lower alkoxycarbonylamino, tetrazolyl, pyridyl, or pyridyloxy; each tetrazolyl or pyridyl group optionally substituted with halogen, cyano, lower alkyl, lower haloalkyl, or lower alkoxy, with the proviso that when R1 is lower dialkylaminophenyl, R3 and R4 are each trifluoromethoxyphenyl.
39. A composition of claim 38 in which R1 is lower dialkylaminophenyl.
40. The composition of claim 39 in which R1 is dimethylaminophenyl.
41. A composition of claim 38 in which
R1 is phenyl substituted in the 4-position with lower alkoxycarbonylamino, tetrazol-4-yl or pyrid-2-yloxy; each tetrazolyl or pyridyl group optionally substituted with lower alkyl, lower haloalkyl, or lower alkoxy; and
R3 and R4 are independently selected from 4-trifluoromethylphenyl and 4-trifluoromethoxyphenyl.
42. A composition of claim 41 in which R3 and R4 are each 4-trifluoromethylphenyl.
43. The composition of claim 42 in which R1 is N-4-(methoxycarbonylamino)phenyl.
44. The composition of claim 42 in which R1 is N-4-(1-methylethoxycarbonylamino)phenyl.
45. The composition of claim 42 in which R1 is N-4-(1-methyl-1,2,3,5-(1-H)-tetrazol-4-yl)phenyl.
46. The composition of claim 42 in which R1 is N-4-[l-(2-fluorooethyl)-1,2,3,5-(1-H)-tetrazol-4-yl]phenyl.
47. The composition of claim 42 in which R1 is N-4-(pyrid-2-yloxy)phenyl.
48. The composition of claim 34 in which said compound is N-[bis(4-trifluoromethoxyphenyl)methyl]piperazine.
49. A method for controlling insects, comprising the steps of identifying a locus where insect control is needed and applying to said locus at least one compound of the formula
Figure USH0002007-20011204-C00126
in which:
A and B are independently selected from lower alkyl;
U is selected from lower alkylidine, lower alkenylidene, and CH—Z, where Z is independently selected from hydrogen, lower alkyl, lower cycloalkyl, and phenyl;
R is selected from phenyl, optionally substituted with halogen, lower alkyl, lower alkoxy, phenyl, or phenoxy, and from a dibenzocyclo(C5-8)alkyl, optionally substituted with halogen, lower alkyl, or lower alkoxy; and
Figure USH0002007-20011204-C00127
 where R3 and R4 are independently selected from phenyl, optionally substituted with, halogen, lower alkyl, lower haloalkyl, lower alkoxy, lower haloalkoxy, lower alkenyl, or phenyl;
R1 is phenyl, naphthyl, tetrazolylphenyl, phenylcyclopropyl, phenoxyphenyl, benzyloxyphenyl, pyridylphenyl, pyridyloxyphenyl, thiadiazolyloxyphenyl, benzothienyl, benzimidazolyl, indolyl, pyrrolyl, or quinolyl, each optionally substituted with halogen, cyano, hydroxy, lower alkyl, lower haloalkyl, lower alkoxy, amino, lower dialkylamino, nitro, lower haloalkylsulfonyloxy, lower alkoxycarbonyl, lower alkoxyalkoxycarbonyl, lower cycloalkylalkoxycarbonyl, lower alkoxyalkylalkoxycarbonyl, lower alkoxycarbonylamino, alkoxythiocarbonylamino, lower alkyldithiocarbonylamino, lower dialkyldioxolylalkoxycarbonylamino, or halophenylamino; or lower alkyl substituted with any one of the foregoing cyclic R1 groups; or 3-R2, where R2 is
Figure USH0002007-20011204-C00128
 where D, E, and G are independently selected from hydrogen, hydroxy, halogen, cyano, lower alkyl, lower haloalkyl, lower alkoxy, nitro, lower haloalkylsulfonyloxy, lower alkylcarboxylato, lower alkylcarbonylamino, arylcarbonylamino, lower alkylcarbonyl. lower alkoxycarbonyl, or D and E taken together form the group —O(CH2)O—, and J is hydrogen or lower alkyl;
m is 2 or 3 and n is 1, 2, or 3;
halogen is chlorine, fluorine, or bromine, lower means having from 1 to 6 carbon atoms, and any aliphatic chain of three or more carbons may be straight or branched.
US08/780,371 1996-01-19 1997-01-09 Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines Abandoned USH2007H1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US08/780,371 USH2007H1 (en) 1996-01-19 1997-01-09 Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines
AU15809/97A AU1580997A (en) 1996-01-19 1997-01-15 Insecticidal n-heterocyclylalkyl- or n-{(polycyclyl)-alkyl}-n'-substituted piperazines
PCT/US1997/000804 WO1997026252A1 (en) 1996-01-19 1997-01-15 Insecticidal n-heterocyclylalkyl- or n-[(polycyclyl)-alkyl]-n'-substituted piperazines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1023796P 1996-01-19 1996-01-19
US08/780,371 USH2007H1 (en) 1996-01-19 1997-01-09 Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines

Publications (1)

Publication Number Publication Date
USH2007H1 true USH2007H1 (en) 2001-12-04

Family

ID=26680947

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/780,371 Abandoned USH2007H1 (en) 1996-01-19 1997-01-09 Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines

Country Status (3)

Country Link
US (1) USH2007H1 (en)
AU (1) AU1580997A (en)
WO (1) WO1997026252A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849630B2 (en) * 1999-07-06 2005-02-01 Vertex Pharmaceuticals Incorporated Cyclized amino acid derivatives
US20050124620A1 (en) * 2002-04-09 2005-06-09 Martyn Frederickson Pharmaceutical compounds

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9709972D0 (en) * 1997-05-19 1997-07-09 Pfizer Ltd Tetrazoles
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6867209B1 (en) 1998-05-22 2005-03-15 Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase
US6340685B1 (en) 1998-05-22 2002-01-22 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6448257B1 (en) 1998-05-22 2002-09-10 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6130235A (en) * 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
AU772477B2 (en) 1998-08-28 2004-04-29 Scios Inc. Inhibitors of p38-alpha kinase
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6020355A (en) * 1999-04-07 2000-02-01 Dekeyser; Mark Achiel Pesticidal tetrazole derivatives
IL146309A (en) 1999-05-21 2008-03-20 Scios Inc INDOLE-TYPE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AS INHIBITORS OF p38 KINASE
US6541477B2 (en) 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
TR200201683T2 (en) * 1999-12-30 2002-12-23 H. Lundbeck A/S Substituted phenyl-piperazine derivatives, their preparation and uses
ATE261958T1 (en) * 1999-12-30 2004-04-15 Lundbeck & Co As H PHENYLPIPERAZINYL DERIVATIVES
CA2429382A1 (en) 2000-11-20 2002-06-06 Scios Inc. Indole-type inhibitors of p38 kinase
JP2004533989A (en) 2000-11-20 2004-11-11 サイオス インコーポレイテッド Piperidine / piperazine type inhibitors of p38 kinase
US6821966B2 (en) 2000-11-20 2004-11-23 Scios, Inc. Inhibitors of p38 kinase
JP2006506346A (en) 2002-09-03 2006-02-23 サイオス インク. Indole derivatives as p38 kinase inhibitors
EP1560582A4 (en) 2002-10-09 2008-03-12 Scios Inc AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
KR20050085673A (en) * 2002-12-18 2005-08-29 에프엠씨 코포레이션 N-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and piperazines
US7314880B2 (en) * 2003-01-02 2008-01-01 Mount Cook Biosciences, Inc. Cardioprotective delta opioid receptor agonists and methods of using same
EP1927594A1 (en) * 2003-01-14 2008-06-04 Arena Pharmaceuticals, Inc. 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
DK1599468T3 (en) * 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prevention and treatment of disorders associated therewith such as diabetes and hyperglycemia
AR045047A1 (en) 2003-07-11 2005-10-12 Arena Pharm Inc ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
EP1915356A1 (en) * 2005-08-08 2008-04-30 AstraZeneca AB Therapeutic agents
ITRM20060090A1 (en) * 2006-02-22 2007-08-23 Sigma Tau Ind Farmaceuti NEW COMPOUNDS CPT INHIBITORS AT LEVEL OF THE SNC AS ANTI-DIABETIC AND OR ANTI-BESIDE DRUGS
SG188548A1 (en) 2010-09-22 2013-04-30 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
JP6838744B2 (en) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ, インコーポレイテッド (R) -2- (7- (4-cyclopentyl-3- (trifluoromethyl) benzyloxy) -1,2,3,4-tetrahydrocyclopenta [b] indole-for use in S1P1 receptor-related disorders Crystalline L-arginine salt of 3-yl) acetic acid (Compound 1)
CN105198788A (en) * 2015-09-30 2015-12-30 蒋军荣 Indole oxoacetyl (N-diaryl methyl) piperazine derivatives and preparation method and application thereof
EP3670498A1 (en) * 2018-12-17 2020-06-24 Gottfried Wilhelm Leibniz Universität Hannover Compounds for treatment of hepaci virus infection and method for determining therapy of hepaci virus infection, in particular, hcv infection

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB944443A (en) 1959-09-25 1900-01-01
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US3920442A (en) 1972-09-18 1975-11-18 Du Pont Water-dispersible pesticide aggregates
US4179505A (en) 1977-03-30 1979-12-18 Janssen Pharmaceutica N.V. 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives
US4935426A (en) * 1988-02-09 1990-06-19 Basf Aktiengesellschaft N,N'-disubstituted piperazines
EP0496692A1 (en) 1991-01-24 1992-07-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) 2-Methoxyphenylpiperazine derivatives
US5166205A (en) 1990-07-26 1992-11-24 Laboratorios Del Dr. Esteve, S. A. Derivatives of 1-diphenylmethyl piperazine and their use as antihistamines
US5418237A (en) 1991-01-22 1995-05-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Indole derivatives

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB944443A (en) 1959-09-25 1900-01-01
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US3920442A (en) 1972-09-18 1975-11-18 Du Pont Water-dispersible pesticide aggregates
US4179505A (en) 1977-03-30 1979-12-18 Janssen Pharmaceutica N.V. 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives
US4935426A (en) * 1988-02-09 1990-06-19 Basf Aktiengesellschaft N,N'-disubstituted piperazines
US5166205A (en) 1990-07-26 1992-11-24 Laboratorios Del Dr. Esteve, S. A. Derivatives of 1-diphenylmethyl piperazine and their use as antihistamines
US5418237A (en) 1991-01-22 1995-05-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Indole derivatives
EP0496692A1 (en) 1991-01-24 1992-07-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) 2-Methoxyphenylpiperazine derivatives

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Benzylpiperazine Derivatives, V. Quantitative Structure-Activity Relationships of 1-Benzyl-4-diphenylmethylpiperazine Derivatives for Cerebral Vasodilating Activity," H. Ohtaka et al., Chem. Pharm. Bull., vol. 35(10), 1987, pp. 4117-4123.*
"sigma Ligands with Subnanomolar Affinity and Preference for the sigma2 Binding Site. 1. 3-(omega-Aminoalkyl)-1H-Indoles," Perregaard et al., J. Med. Chem., 1995, 38, pp. 1998-2008.*
"σ Ligands with Subnanomolar Affinity and Preference for the σ2 Binding Site. 1. 3-(ω-Aminoalkyl)-1H-Indoles," Perregaard et al., J. Med. Chem., 1995, 38, pp. 1998-2008.*
Ohtaka et al., "Benzylpiperazine Derivatives. IV. Syntheses and Cerebral Vasodilating Activities of 1-Benzyl-4-diphenylmethyl-piperazine Derivatives", Chem. Pharm. Bull., 1987, 35(8), 3270-3275.
Ohtaka et al., "Benzylpiperazine Derivatives. VI. Design and Syntheses of Vinylogs of 1-Benzyl-4-diphenylmethylpiperazine Derivatives and Their Cerebral Vasodilating Activities", Chem. Pharm. Bull., 1987, 35(10), 4124-4129.
Venero et al., "Process for the preparation of nes (diphenylmethyl)piperazine derivatives as antihistaminics and antiallergics", Chem. Abstr., 1993, 118 (5), Abstract No. 38948h.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849630B2 (en) * 1999-07-06 2005-02-01 Vertex Pharmaceuticals Incorporated Cyclized amino acid derivatives
US20050124620A1 (en) * 2002-04-09 2005-06-09 Martyn Frederickson Pharmaceutical compounds

Also Published As

Publication number Publication date
WO1997026252A1 (en) 1997-07-24
AU1580997A (en) 1997-08-11

Similar Documents

Publication Publication Date Title
USH2007H1 (en) Insecticidal N-heterocyclylalkyl-or N-[(polycyclyl)alkyl]-N′substituted piperazines
US4871753A (en) 3-Phenyl-5-trifluoromethyl-1,2,4-oxadiazole compounds which are useful pesticides
AU696016B2 (en) Herbicidal heterocyclic-substituted pyridines
US6214845B1 (en) Insecticidal N-(substituted arylmethyl)-4[bis(substituted phenyl or pyridyl)methyl] piperidines
RU2097375C1 (en) Fungicide composition, method of fungi control, piperidine derivatives and a method of their synthesis
JPS6248680A (en) Nitromethylene derivative, production thereof and insecticide
EP0132606B1 (en) Benzimidazole derivatives, and their production and use
US5569664A (en) Insecticidal n-(substituted arylmethyl)-4-[bis(substituted phenyl) methyl]pi
KR20060006065A (en) Phenyl substituted cyclic derivatives
JPH024566B2 (en)
JPH04234370A (en) Tetrahydropyrimidine derivative
HU194481B (en) Fungicide composition containing ethane derivatives and process for producing the active agents
US5319092A (en) 1-dimethylcarbamoyl-3-substituted-5-substituted-1H-1,2,4-triazoles
US4696938A (en) Insecticidal 6-aryl-pyridine thiosemicarbazones
US5661108A (en) Herbicidal 3-(bicyclic nitrogen-containing heterocycle)-substituted-1-methyl-6-trifluoromethyluracils
US5399543A (en) 3-[4-(phenylmethoxy)phenyl]-1-substituted-6-haloalkyl-uracil herbicides
US6017931A (en) Insecticidal compositions containing n-(substituted phenylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
EP0844825B1 (en) Insecticidal n-(substituted arylmethyl)-4- bis(substituted phenyl or pyridyl)methyl]piperidines
US5310723A (en) Herbicidal 3-(1-substituted-quinolin-2-on-7-yl)-1-substituted-6-trifluoromethyluracils
US5939438A (en) Insecticidal oximino and hydrazono derivatives of N-benzyl-4-benzhydryl-and N-benzyl-4-benzhydrol-piperidines
RU2130021C1 (en) Picolineamide derivatives, method of preparing thereof, pyridine-6-carbonitrile, herbicidal composition, methods of controlling undesired vegetation
US5693594A (en) Herbicidal thiazole derivatives
US6030987A (en) Insecticidal N-(substituted arylmethyl)-4-[bis(substituted phenyl or pyridyl)methyl]piperidines
US4894084A (en) Substituted quinolinonyl and dihydroquinolinonyl triazolinone herbicides
JPH0647578B2 (en) Aralkylaminopyrimidine derivatives, a method for producing the same, and insecticides, acaricides and fungicides containing the derivatives as active ingredients

Legal Events

Date Code Title Description
AS Assignment

Owner name: FMC CORPORATION, PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SILVERMAN, IAN R.;ALI, SYED F.;COHEN, DANIEL H.;AND OTHERS;REEL/FRAME:009065/0952;SIGNING DATES FROM 19980318 TO 19980323

STCF Information on status: patent grant

Free format text: PATENTED CASE